Claus Garbe

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/1691756/publications.pdf

Version: 2024-02-01

755 papers	66,982 citations	1043 113 h-index	1024 235 g-index
879 all docs	879 docs citations	879 times ranked	44054 citing authors

#	Article	IF	Citations
1	Improved Survival with Vemurafenib in Melanoma with BRAF V600E Mutation. New England Journal of Medicine, 2011, 364, 2507-2516.	13.9	6,976
2	Ipilimumab plus Dacarbazine for Previously Untreated Metastatic Melanoma. New England Journal of Medicine, 2011, 364, 2517-2526.	13.9	4,074
3	Improved Survival with MEK Inhibition in BRAF-Mutated Melanoma. New England Journal of Medicine, 2012, 367, 107-114.	13.9	1,976
4	Combined Vemurafenib and Cobimetinib in BRAF-Mutated Melanoma. New England Journal of Medicine, 2014, 371, 1867-1876.	13.9	1,824
5	Melanoma staging: Evidenceâ€based changes in the American Joint Committee on Cancer eighth edition cancer staging manual. Ca-A Cancer Journal for Clinicians, 2017, 67, 472-492.	157.7	1,662
6	Combined BRAF and MEK Inhibition versus BRAF Inhibition Alone in Melanoma. New England Journal of Medicine, 2014, 371, 1877-1888.	13.9	1,572
7	Dabrafenib and trametinib versus dabrafenib and placebo for Val600 BRAF-mutant melanoma: a multicentre, double-blind, phase 3 randomised controlled trial. Lancet, The, 2015, 386, 444-451.	6.3	1,175
8	Five-Year Outcomes with Dabrafenib plus Trametinib in Metastatic Melanoma. New England Journal of Medicine, 2019, 381, 626-636.	13.9	909
9	Safety and efficacy of vemurafenib in BRAFV600E and BRAFV600K mutation-positive melanoma (BRIM-3): extended follow-up of a phase 3, randomised, open-label study. Lancet Oncology, The, 2014, 15, 323-332.	5.1	890
10	Cobimetinib combined with vemurafenib in advanced BRAFV600-mutant melanoma (coBRIM): updated efficacy results from a randomised, double-blind, phase 3 trial. Lancet Oncology, The, 2016, 17, 1248-1260.	5.1	832
11	Encorafenib plus binimetinib versus vemurafenib or encorafenib in patients with BRAF -mutant melanoma (COLUMBUS): a multicentre, open-label, randomised phase 3 trial. Lancet Oncology, The, 2018, 19, 603-615.	5.1	751
12	Phase III Randomized Clinical Trial Comparing Tremelimumab With Standard-of-Care Chemotherapy in Patients With Advanced Melanoma. Journal of Clinical Oncology, 2013, 31, 616-622.	0.8	720
13	Dermcidin: a novel human antibiotic peptide secreted by sweat glands. Nature Immunology, 2001, 2, 1133-1137.	7.0	614
14	Epidemiology of Melanoma and Nonmelanoma Skin Cancerâ€"The Role of Sunlight. Advances in Experimental Medicine and Biology, 2008, 624, 89-103.	0.8	582
15	Complete lymph node dissection versus no dissection in patients with sentinel lymph node biopsy positive melanoma (DeCOG-SLT): a multicentre, randomised, phase 3 trial. Lancet Oncology, The, 2016, 17, 757-767.	5.1	562
16	Melanoma epidemiology and trends. Clinics in Dermatology, 2009, 27, 3-9.	0.8	556
17	Dabrafenib plus trametinib versus dabrafenib monotherapy in patients with metastatic BRAF V600E/K-mutant melanoma: long-term survival and safety analysis of a phase 3 study. Annals of Oncology, 2017, 28, 1631-1639.	0.6	549
18	Cutaneous, gastrointestinal, hepatic, endocrine, and renal side-effects of anti-PD-1 therapy. European Journal of Cancer, 2016, 60, 190-209.	1.3	546

#	Article	IF	Citations
19	Results of a Phase III, Randomized, Placebo-Controlled Study of Sorafenib in Combination With Carboplatin and Paclitaxel As Second-Line Treatment in Patients With Unresectable Stage III or Stage IV Melanoma. Journal of Clinical Oncology, 2009, 27, 2823-2830.	0.8	517
20	Neurological, respiratory, musculoskeletal, cardiac and ocular side-effects of anti-PD-1 therapy. European Journal of Cancer, 2016, 60, 210-225.	1.3	490
21	Randomized, Open-Label Phase II Study Evaluating the Efficacy and Safety of Talimogene Laherparepvec in Combination With Ipilimumab Versus Ipilimumab Alone in Patients With Advanced, Unresectable Melanoma. Journal of Clinical Oncology, 2018, 36, 1658-1667.	0.8	483
22	Baseline Biomarkers for Outcome of Melanoma Patients Treated with Pembrolizumab. Clinical Cancer Research, 2016, 22, 5487-5496.	3.2	480
23	Systematic Review of Medical Treatment in Melanoma: Current Status and Future Prospects. Oncologist, 2011, 16, 5-24.	1.9	472
24	Overall survival in patients with BRAF-mutant melanoma receiving encorafenib plus binimetinib versus vemurafenib or encorafenib (COLUMBUS): a multicentre, open-label, randomised, phase 3 trial. Lancet Oncology, The, 2018, 19, 1315-1327.	5.1	469
25	Tumor Lymphangiogenesis. American Journal of Pathology, 2003, 162, 1951-1960.	1.9	463
26	Baseline Peripheral Blood Biomarkers Associated with Clinical Outcome of Advanced Melanoma Patients Treated with Ipilimumab. Clinical Cancer Research, 2016, 22, 2908-2918.	3.2	459
27	Acral cutaneous melanoma in caucasians: clinical features, histopathology and prognosis in 112 patients. British Journal of Dermatology, 2000, 143, 275-280.	1.4	453
28	Five-Year Survival Rates for Treatment-Naive Patients With Advanced Melanoma Who Received Ipilimumab Plus Dacarbazine in a Phase III Trial. Journal of Clinical Oncology, 2015, 33, 1191-1196.	0.8	445
29	Ipilimumab 10 mg/kg versus ipilimumab 3 mg/kg in patients with unresectable or metastatic melanoma: a randomised, double-blind, multicentre, phase 3 trial. Lancet Oncology, The, 2017, 18, 611-622.	5.1	428
30	Melanoma. Nature Reviews Disease Primers, 2015, 1, 15003.	18.1	417
31	The Price of Tumor Control: An Analysis of Rare Side Effects of Anti-CTLA-4 Therapy in Metastatic Melanoma from the Ipilimumab Network. PLoS ONE, 2013, 8, e53745.	1.1	414
32	Diagnosis and treatment of melanoma. European consensus-based interdisciplinary guideline â€“ Update 2012. European Journal of Cancer, 2012, 48, 2375-2390.	1.3	407
33	Epidemiology of Skin Cancer. , 2014, 810, 120-140.		406
34	Diagnosis and treatment of invasive squamous cell carcinoma of the skin: European consensus-based interdisciplinary guideline. European Journal of Cancer, 2015, 51, 1989-2007.	1.3	404
35	Binimetinib versus dacarbazine in patients with advanced NRAS-mutant melanoma (NEMO): a multicentre, open-label, randomised, phase 3 trial. Lancet Oncology, The, 2017, 18, 435-445.	5.1	399
36	Diagnosis and treatment of basal cell carcinoma: European consensusâ€“based interdisciplinary guidelines. European Journal of Cancer, 2019, 118, 10-34.	1.3	345

#	Article	IF	Citations
37	Diagnosis and treatment of melanoma. European consensus-based interdisciplinary guideline â€“ Update 2016. European Journal of Cancer, 2016, 63, 201-217.	1.3	330
38	Improving Melanoma Classification by Integrating Genetic and Morphologic Features. PLoS Medicine, 2008, 5, e120.	3.9	322
39	Diagnosis and treatment of Merkel Cell Carcinoma. European consensus-based interdisciplinary guideline. European Journal of Cancer, 2015, 51, 2396-2403.	1.3	320
40	Evolving Strategies for the Management of Handâ€“Foot Skin Reaction Associated with the Multitargeted Kinase Inhibitors Sorafenib and Sunitinib. Oncologist, 2008, 13, 1001-1011.	1.9	315
41	Direct Injection of Protamine-protected mRNA: Results of a Phase 1/2 Vaccination Trial in Metastatic Melanoma Patients. Journal of Immunotherapy, 2009, 32, 498-507.	1.2	301
42	Palliative therapy of disseminated malignant melanoma: a systematic review of 41 randomised clinical trials. Lancet Oncology, The, 2003, 4, 748-759.	5.1	292
43	Long-term safety and efficacy of vismodegib in patients with advanced basal cell carcinoma: final update of the pivotal ERIVANCE BCC study. BMC Cancer, 2017, 17, 332.	1.1	291
44	Diagnosis and treatment of melanoma: European consensus-based interdisciplinary guideline. European Journal of Cancer, 2010, 46, 270-283.	1.3	284
45	Metastatic pathways and time courses in the orderly progression of cutaneous melanoma. British Journal of Dermatology, 2002, 147, 62-70.	1.4	277
46	Cathelicidin Anti-Microbial Peptide Expression in Sweat, an Innate Defense System for the Skin. Journal of Investigative Dermatology, 2002, 119, 1090-1095.	0.3	249
47	Deficiency of Dermcidin-Derived Antimicrobial Peptides in Sweat of Patients with Atopic Dermatitis Correlates with an Impaired Innate Defense of Human Skin In Vivo. Journal of Immunology, 2005, 174, 8003-8010.	0.4	248
48	Prospective Evaluation of a Follow-Up Schedule in Cutaneous Melanoma Patients: Recommendations for an Effective Follow-Up Strategy. Journal of Clinical Oncology, 2003, 21, 520-529.	0.8	247
49	Risk Factors for Developing Cutaneous Melanoma and Criteria for Identifying Persons at Risk: Multicenter Case-Control Study of the Central Malignant Melanoma Registry of the German Dermatological Society. Journal of Investigative Dermatology, 1994, 102, 695-699.	0.3	246
50	Vemurafenib in patients with BRAFV600 mutated metastatic melanoma: an open-label, multicentre, safety study. Lancet Oncology, The, 2014, 15, 436-444.	5.1	242
51	Survival of patients with advanced metastatic melanoma: the impact of novel therapiesâ€“update 2017. European Journal of Cancer, 2017, 83, 247-257.	1.3	236
52	The RAS/RAF/MEK/ERK and PI3K/AKT signaling pathways present molecular targets for the effective treatment of advanced melanoma. Frontiers in Bioscience - Landmark, 2005, 10, 2986.	3.0	227
53	Adjuvant pembrolizumab versus placebo in resected stage III melanoma (EORTC 1325-MG/KEYNOTE-054): distant metastasis-free survival results from a double-blind, randomised, controlled, phase 3 trial. Lancet Oncology, The, 2021, 22, 643-654.	5.1	224
54	Borrelia burgdorferiâ€”associated cutaneous B cell lymphoma: Clinical and immunohistologic characterization of four cases. Journal of the American Academy of Dermatology, 1991, 24, 584-590.	0.6	222

#	Article	IF	Citations
55	Myeloid-Derived Suppressor Cells Predict Survival of Patients with Advanced Melanoma: Comparison with Regulatory T Cells and NY-ESO-1- or Melan-Aâ€“Specific T Cells. Clinical Cancer Research, 2014, 20, 1601-1609.	3.2	222
56	Primary cutaneous melanoma. Identification of prognostic groups and estimation of individual prognosis for 5093 patients. Cancer, 1995, 75, 2484-2491.	2.0	221
57	Results of the First Phase I/II Clinical Vaccination Trial With Direct Injection of mRNA. Journal of Immunotherapy, 2008, 31, 180-188.	1.2	216
58	The natural course of cutaneous melanoma. Journal of Surgical Oncology, 2004, 86, 172-178.	0.8	215
59	Primary cutaneous melanoma. Prognostic classification of anatomic location. Cancer, 1995, 75, 2492-2498.	2.0	211
60	Age and gender are significant independent predictors of survival in primary cutaneous melanoma. Cancer, 2008, 112, 1795-1804.	2.0	211
61	Human Melanoma Progression in Skin Reconstructs. American Journal of Pathology, 2000, 156, 193-200.	1.9	203
62	Phase II DeCOG-Study of Ipilimumab in Pretreated and Treatment-NaÃ¯ve Patients with Metastatic Uveal Melanoma. PLoS ONE, 2015, 10, e0118564.	1.1	197
63	Diagnosis and treatment of cutaneous melanoma: state of the art 2006*. Melanoma Research, 2007, 17, 117-127.	0.6	192
64	Prospective comparison of 18F-fluorodeoxyglucose positron emission tomography/computed tomography and whole-body magnetic resonance imaging in staging of advanced malignant melanoma. European Journal of Cancer, 2007, 43, 557-564.	1.3	188
65	Adjuvant nivolumab plus ipilimumab or nivolumab monotherapy versus placebo in patients with resected stage IV melanoma with no evidence of disease (IMMUNED): a randomised, double-blind, placebo-controlled, phase 2 trial. Lancet, The, 2020, 395, 1558-1568.	6.3	188
66	Epidemiology of Skin Cancer: Update 2019. Advances in Experimental Medicine and Biology, 2020, 1268, 123-139.	0.8	184
67	Final Results of Phase III SYMMETRY Study: Randomized, Double-Blind Trial of Elesclomol Plus Paclitaxel Versus Paclitaxel Alone As Treatment for Chemotherapy-Naive Patients With Advanced Melanoma. Journal of Clinical Oncology, 2013, 31, 1211-1218.	0.8	182
68	European interdisciplinary guideline on invasive squamous cell carcinoma of the skin: Part 2. Treatment. European Journal of Cancer, 2020, 128, 83-102.	1.3	181
69	Vemurafenib in metastatic melanoma patients with brain metastases: an open-label, single-arm, phase 2, multicentre study. Annals of Oncology, 2017, 28, 634-641.	0.6	179
70	Ultrasound examination of regional lymph nodes significantly improves early detection of locoregional metastases during the follow-up of patients with cutaneous melanoma. Cancer, 2000, 88, 2534-2539.	2.0	171
71	Human Papillomaviruses are Commonly Found in Normal Skin of Immunocompetent Hosts. Journal of Investigative Dermatology, 1998, 110, 752-755.	0.3	168
72	Phase II trial of intralesional therapy with interleukin-2 in soft-tissue melanoma metastases. British Journal of Cancer, 2003, 89, 1620-1626.	2.9	167

#	Article	IF	Citations
73	Primary cutaneous melanoma. Optimized cutoff points of tumor thickness and importance of clark's level for prognostic classification. Cancer, 1995, 75, 2499-2506.	2.0	166
74	Acquired Melanocytic Nevi as Risk Factor for Melanoma Development. A Comprehensive Review of Epidemiological Data. Pigment Cell & Melanoma Research, 2003, 16, 297-306.	4.0	163
75	Examination of Regional Lymph Nodes by Sentinel Node Biopsy and Molecular Analysis Provides New Staging Facilities in Primary Cutaneous Melanoma. Journal of Investigative Dermatology, 2000, 114, 637-642.	0.3	162
76	Basal cell carcinoma: histological classification and body-site distribution. British Journal of Dermatology, 2006, 155, 401-407.	1.4	162
77	Associated Factors in the Prevalence of More Than 50 Common Melanocytic Nevi, Atypical Melanocytic Nevi, and Actinic Lentigines: Multicenter Case-Control Study of the Central Malignant Melanoma Registry of the German Dermatolgocial Society. Journal of Investigative Dermatology, 1994, 102, 700-705.	0.3	160
78	Three-year pooled analysis of factors associated with clinical outcomes across dabrafenib and trametinib combination therapy phase 3 randomised trials. European Journal of Cancer, 2017, 82, 45-55.	1.3	160
79	Adjuvant interferon-Î± for the treatment of high-risk melanoma: An individual patient data meta-analysis. European Journal of Cancer, 2017, 82, 171-183.	1.3	159
80	Final Analysis of DeCOG-SLT Trial: No Survival Benefit for Complete Lymph Node Dissection in Patients With Melanoma With Positive Sentinel Node. Journal of Clinical Oncology, 2019, 37, 3000-3008.	0.8	155
81	European consensus-based interdisciplinary guideline for melanoma. Part 2: Treatment â€“ Update 2019. European Journal of Cancer, 2020, 126, 159-177.	1.3	154
82	Time trends of cutaneous melanoma in Queensland, Australia and Central Europe. Cancer, 2000, 89, 1269-1278.	2.0	150
83	The prevalence of human papillomavirus genotypes in nonmelanoma skin cancers of nonimmunosuppressed individuals identifies high-risk genital types as possible risk factors. Cancer Research, 2003, 63, 7515-9.	0.4	150
84	Incidence, Mortality, and Trends of Nonmelanoma Skin Cancer in Germany. Journal of Investigative Dermatology, 2017, 137, 1860-1867.	0.3	149
85	Determinants of survival in patients with brain metastases from cutaneous melanoma. British Journal of Cancer, 2010, 102, 1213-1218.	2.9	147
86	Increases in Absolute Lymphocytes and Circulating CD4+ and CD8+ T Cells Are Associated with Positive Clinical Outcome of Melanoma Patients Treated with Ipilimumab. Clinical Cancer Research, 2016, 22, 4848-4858.	3.2	146
87	Epidemiology of Cutaneous Melanoma in Germany and Worldwide. Skin Pharmacology and Physiology, 2001, 14, 280-290.	1.1	142
88	Oncogenic GNAQ mutations are not correlated with disease-free survival in uveal melanoma. British Journal of Cancer, 2009, 101, 813-815.	2.9	139
89	Assessment of nivolumab exposure and clinical safety of 480â€‰mg every 4 weeks flat-dosing schedule in patients with cancer. Annals of Oncology, 2018, 29, 2208-2213.	0.6	139
90	HLA-A2 Restricted, Melanocyte-Specific CD8+ T Lymphocytes Detected in Vitiligo Patients are Related to Disease Activity and are Predominantly Directed Against MelanA/MART1. Journal of Investigative Dermatology, 2001, 116, 891-897.	0.3	138

#	Article	IF	Citations
91	Survival of patients with advanced metastatic melanoma: The impact of novel therapies. European Journal of Cancer, 2016, 53, 125-134.	1.3	137
92	Tumor mutation burden and circulating tumor DNA in combined CTLA-4 and PD-1 antibody therapy in metastatic melanoma â€“ results of a prospective biomarker study. , 2019, 7, 180.		137
93	"Functional" Surgery in Subungual Melanoma. Dermatologic Surgery, 2003, 29, 366-374.	0.4	135
94	Digital image analysis for diagnosis of cutaneous melanoma. Development of a highly effective computer algorithm based on analysis of 837 melanocytic lesions. British Journal of Dermatology, 2004, 151, 1029-1038.	1.4	134
95	A Dose-Escalation and Signal-Generating Study of the Immunocytokine L19-IL2 in Combination with Dacarbazine for the Therapy of Patients with Metastatic Melanoma. Clinical Cancer Research, 2011, 17, 7732-7742.	3.2	134
96	Expression of interleukin 10 in human melanoma. British Journal of Cancer, 1994, 70, 1182-1185.	2.9	133
97	European consensus-based interdisciplinary guideline for melanoma. Part 1: Diagnostics â€“ Update 2019. European Journal of Cancer, 2020, 126, 141-158.	1.3	133
98	Prolonged survival of 2 years or longer for patients with disseminated melanoma. Cancer, 1997, 79, 2345-2353.	2.0	132
99	European interdisciplinary guideline on invasive squamous cell carcinoma of the skin: Part 1. epidemiology, diagnostics and prevention. European Journal of Cancer, 2020, 128, 60-82.	1.3	131
100	Genetic and morphologic features for melanoma classification. Pigment Cell and Melanoma Research, 2010, 23, 763-770.	1.5	130
101	Update on tolerability and overall survival in COLUMBUS: landmark analysis of a randomised phase 3 trial of encorafenib plus binimetinib vs vemurafenib or encorafenib in patients with BRAF V600â€“mutant melanoma. European Journal of Cancer, 2020, 126, 33-44.	1.3	130
102	Combined Inhibition of MAPK and mTOR Signaling Inhibits Growth, Induces Cell Death, and Abrogates Invasive Growth of Melanoma Cells. Journal of Investigative Dermatology, 2008, 128, 2013-2023.	0.3	129
103	Serum markers lactate dehydrogenase and S100B predict independently disease outcome in melanoma patients with distant metastasis. British Journal of Cancer, 2012, 107, 422-428.	2.9	129
104	Moderate sun exposure and nevus counts in parents are associated with development of melanocytic nevi in childhood. Cancer, 2003, 97, 628-638.	2.0	127
105	Targeting hyperactivation of the <scp>AKT</scp> survival pathway to overcome therapy resistance of melanoma brain metastases. Cancer Medicine, 2013, 2, 76-85.	1.3	126
106	Survival of Patients with Cutaneous Squamous Cell Carcinoma: Results of aÂProspective Cohort Study. Journal of Investigative Dermatology, 2017, 137, 2309-2315.	0.3	124
107	Dermoscopic Classification of Atypical Melanocytic Nevi (Clark Nevi). Archives of Dermatology, 2001, 137, 1575-80.	1.7	122
108	Adjuvant low-dose interferon Î±2a with or without dacarbazine compared with surgery alone: a prospective-randomized phase III DeCOG trial in melanoma patients with regional lymph node metastasis. Annals of Oncology, 2008, 19, 1195-1201.	0.6	122

#	Article	IF	Citations
109	Malignant Melanoma S3-Guideline â€œDiagnosis, Therapy and Follow-up of Melanomaâ€. JDDG - Journal of the German Society of Dermatology, 2013, 11, 1-116.	0.4	122
110	Prognostic impact of the type of anaesthesia used during the excision of primary cutaneous melanoma. Melanoma Research, 2000, 10, 165-169.	0.6	120
111	High response rate after intratumoral treatment with interleukinâ€2. Cancer, 2010, 116, 4139-4146.	2.0	120
112	Diagnosis and treatment of Kaposi's sarcoma: European consensus-based interdisciplinary guideline (EDF/EADO/EORTC). European Journal of Cancer, 2019, 114, 117-127.	1.3	120
113	The incidence and mortality of cutaneous melanoma in southern Germany. Cancer, 2006, 107, 1331-1339.	2.0	119
114	Number of metastases, serum lactate dehydrogenase level, and type of treatment are prognostic factors in patients with brain metastases of malignant melanoma. Cancer, 2011, 117, 1697-1703.	2.0	118
115	Metastatic melanoma of unknown primary origin shows prognostic similarities to regional metastatic melanoma. Cancer, 1997, 80, 60-65.	2.0	117
116	Inhibition of PI3K-AKT-mTOR Signaling Sensitizes Melanoma Cells to Cisplatin and Temozolomide. Journal of Investigative Dermatology, 2009, 129, 1500-1515.	0.3	116
117	Diagnostic value and prognostic significance of protein S-100?, melanoma-inhibitory activity, and tyrosinase/MART-1 reverse transcription-polymerase chain reaction in the follow-up of high-risk melanoma patients. Cancer, 2003, 97, 1737-1745.	2.0	115
118	Markers and Relative Risk in a German Population for Developing Malignant Melanoma. International Journal of Dermatology, 1989, 28, 517-523.	0.5	114
119	Vemurafenib Potently Induces Endoplasmic Reticulum Stressâ€“Mediated Apoptosis in BRAFV600E Melanoma Cells. Science Signaling, 2013, 6, ra7.	1.6	114
120	Molecular events in melanoma development and progression. Frontiers in Bioscience - Landmark, 1998, 3, d1005-1010.	3.0	113
121	Evidence and interdisciplinary consense-based German guidelines: diagnosis and surveillance of melanoma. Melanoma Research, 2007, 17, 393-399.	0.6	113
122	Response of Psoriasis to Interleukin-10 is Associated with Suppression of Cutaneous Type 1 Inflammation, Downregulation of the Epidermal Interleukin-8/CXCR2 Pathway and Normalization of Keratinocyte Maturation. Journal of Investigative Dermatology, 2001, 116, 319-329.	0.3	112
123	Prognostic Factors of Thin Cutaneous Melanoma: An Analysis of the Central Malignant Melanoma Registry of the German Dermatological Society. Journal of Clinical Oncology, 2004, 22, 3660-3667.	0.8	112
124	Dermcidin is constitutively produced by eccrine sweat glands and is not induced in epidermal cells under inflammatory skin conditions. British Journal of Dermatology, 2004, 151, 534-539.	1.4	112
125	Functional T Cells Targeting NY-ESO-1 or Melan-A Are Predictive for Survival of Patients With Distant Melanoma Metastasis. Journal of Clinical Oncology, 2012, 30, 1835-1841.	0.8	112
126	Phase III, open-label, randomized, comparative study of tremelimumab (CP-675,206) and chemotherapy (temozolomide [TMZ] or dacarbazine [DTIC]) in patients with advanced melanoma. Journal of Clinical Oncology, 2008, 26, LBA9011-LBA9011.	0.8	112

#	Article	IF	Citations
127	Temozolomide in Combination With Interferon-Alfa Versus Temozolomide Alone in Patients With Advanced Metastatic Melanoma: A Randomized, Phase III, Multicenter Study from the Dermatologic Cooperative Oncology Group. Journal of Clinical Oncology, 2005, 23, 9001-9007.	0.8	111
128	Combined targeting of MAPK and AKT signalling pathways is a promising strategy for melanoma treatment. British Journal of Dermatology, 2007, 156, 1204-1213.	1.4	111
129	Desmoplastic Malignant Melanoma: A Clinicopathologic Analysis of 113 Cases. American Journal of Dermatopathology, 2008, 30, 207-215.	0.3	109
130	Diagnosis and treatment of dermatofibrosarcoma protuberans. European consensus-based interdisciplinary guideline. European Journal of Cancer, 2015, 51, 2604-2608.	1.3	109
131	Î²-Catenin Signaling Increases during Melanoma Progression and Promotes Tumor Cell Survival and Chemoresistance. PLoS ONE, 2011, 6, e23429.	1.1	105
132	Surveillance of patients at high risk for cutaneous malignant melanoma using digital dermoscopy. British Journal of Dermatology, 2005, 152, 87-92.	1.4	102
133	European consensus-based interdisciplinary guideline for melanoma. Part 1: Diagnostics: Update 2022. European Journal of Cancer, 2022, 170, 236-255.	1.3	102
134	Naturally Processed Dermcidin-Derived Peptides Do Not Permeabilize Bacterial Membranes and Kill Microorganisms Irrespective of Their Charge. Antimicrobial Agents and Chemotherapy, 2006, 50, 2608-2620.	1.4	101
135	Prospective comparison of the impact on treatment decisions of whole-body magnetic resonance imaging and computed tomography in patients with metastatic malignant melanoma. European Journal of Cancer, 2006, 42, 342-350.	1.3	100
136	The prognosis of primary and metastasising melanoma. An evaluation of the TNM classification in 2,495 patients. British Journal of Cancer, 1992, 66, 856-861.	2.9	99
137	Is head and neck melanoma a distinct entity? A clinical registry-based comparative study in 5702 patients with melanoma. British Journal of Dermatology, 2006, 155, 771-777.	1.4	98
138	Modified ABC-point list of dermoscopy: A simplified and highly accurate dermoscopic algorithm for the diagnosis of cutaneous melanocytic lesions. Journal of the American Academy of Dermatology, 2003, 48, 672-678.	0.6	97
139	Anti-PD-1/PD-L1 immunotherapy in patients with solid organ transplant, HIVÂor hepatitis B/C infection. European Journal of Cancer, 2018, 104, 137-144.	1.3	97
140	The mitogen-activated protein kinase pathway in melanoma part I â€“ Activation and primary resistance mechanisms to BRAF inhibition. European Journal of Cancer, 2017, 73, 85-92.	1.3	96
141	Epidemiologic evidence for the role of melanocytic nevi as risk markers and direct precursors of cutaneous malignant melanoma. Journal of the American Academy of Dermatology, 1992, 26, 920-926.	0.6	94
142	Is morphoea caused by Borrelia burgdorferi? A review. British Journal of Dermatology, 2000, 142, 636-644.	1.4	94
143	Sonidegib and vismodegib in the treatment of patients with locally advanced basal cell carcinoma: a joint expert opinion. Journal of the European Academy of Dermatology and Venereology, 2020, 34, 1944-1956.	1.3	94
144	Development of prognostic factors and survival in cutaneous melanoma over 25 years. Cancer, 2005, 103, 616-624.	2.0	93

#	Article	IF	Citations
145	European consensus-based interdisciplinary guideline for melanoma. Part 2: Treatment - Update 2022. European Journal of Cancer, 2022, 170, 256-284.	1.3	92
146	The increased expression of Y box-binding protein 1 in melanoma stimulates proliferation and tumor invasion, antagonizes apoptosis and enhances chemoresistance. International Journal of Cancer, 2007, 120, 2110-2118.	2.3	90
147	Relapse-Free Survival as a Surrogate for Overall Survival in the Evaluation of Stage IIâ€“III Melanoma Adjuvant Therapy. Journal of the National Cancer Institute, 2018, 110, 87-96.	3.0	89
148	Amplification of MelanA messenger RNA in addition to tyrosinase increases sensitivity of melanoma cell detection in peripheral blood and is associated with the clinical stage and prognosis of malignant melanoma. British Journal of Dermatology, 1999, 141, 30-36.	1.4	88
149	Peripheral CD8 effector-memory type 1 T-cells correlate with outcome in ipilimumab-treated stage IV melanoma patients. European Journal of Cancer, 2017, 73, 61-70.	1.3	88
150	Detection of Melanoma Micrometastasis in Sentinel Nodes by Reverse Transcription-Polymerase Chain Reaction Correlates With Tumor Thickness and Is Predictive of Micrometastatic Disease in the Lymph Node Basin. American Journal of Surgical Pathology, 1999, 23, 822.	2.1	88
151	K + Channels and the Intracellular Calcium Signal in Human Melanoma Cell Proliferation. Journal of Membrane Biology, 1996, 151, 149-157.	1.0	87
152	The adhesion molecule L1 (CD171) promotes melanoma progression. International Journal of Cancer, 2006, 119, 549-555.	2.3	87
153	The Prognostic and Predictive Value of Melanoma-related MicroRNAs Using Tissue and Serum: A MicroRNA Expression Analysis. EBioMedicine, 2015, 2, 671-680.	2.7	86
154	Updated overall survival (OS) results for BRIM-3, a phase III randomized, open-label, multicenter trial comparing BRAF inhibitor vemurafenib (vem) with dacarbazine (DTIC) in previously untreated patients with BRAF^{V600E}-mutated melanoma.. Journal of Clinical Oncology, 2012, 30, 8502-8502.	0.8	86
155	Dacarbazine and interferon Î± with or without interleukin 2 in metastatic melanoma: a randomized phase III multicentre trial of the Dermatologic Cooperative Oncology Group (DeCOG). British Journal of Cancer, 2001, 84, 1036-1042.	2.9	85
156	Cathepsin D Is Present in Human Eccrine Sweat and Involved in the Postsecretory Processing of the Antimicrobial Peptide DCD-1L. Journal of Biological Chemistry, 2006, 281, 5406-5415.	1.6	84
157	A phase III, randomized, open label study to evaluate the safety and efficacy of imiquimod 5% cream appliedÂthrice weekly for 8 and 12 weeks inÂtheÂtreatment of low-risk nodular basalÂcellÂcarcinoma. Journal of the American Academy of Dermatology, 2007, 57, 616-621.	0.6	84
158	Hazard rates for recurrent and secondary cutaneous melanoma: An analysis of 33,384 patients in the German Central Malignant Melanoma Registry. Journal of the American Academy of Dermatology, 2012, 66, 37-45.	0.6	84
159	Survival of patients with advanced metastatic melanoma: The impact of MAP kinase pathway inhibition and immune checkpoint inhibition - Update 2019. European Journal of Cancer, 2020, 130, 126-138.	1.3	84
160	Continuous long-term monitoring of UV radiation in professional mountain guides reveals extremely high exposure. International Journal of Cancer, 2003, 103, 775-778.	2.3	83
161	Evidence and interdisciplinary consensus-based German guidelines: surgical treatment and radiotherapy of melanoma. Melanoma Research, 2008, 18, 61-67.	0.6	83
162	Incisional biopsy and melanoma prognosis: Facts and controversies. Clinics in Dermatology, 2010, 28, 316-318.	0.8	83

#	Article	IF	Citations
163	S100B and LDH as early prognostic markers for response and overall survival in melanoma patients treated with anti-PD-1 or combined anti-PD-1 plus anti-CTLA-4 antibodies. British Journal of Cancer, 2018, 119, 339-346.	2.9	83
164	Short German guidelines: Malignant melanoma. JDDG - Journal of the German Society of Dermatology, 2008, 6, S9-S14.	0.4	82
165	5-Year Outcomes with Cobimetinib plus Vemurafenib in BRAFV600 Mutationâ€“Positive Advanced Melanoma: Extended Follow-up of the coBRIM Study. Clinical Cancer Research, 2021, 27, 5225-5235.	3.2	82
166	Title is missing!. , 2017, , .		82
167	Plasmid DNA- and messenger RNA-based anti-cancer vaccination. Immunology Letters, 2008, 115, 33-42.	1.1	81
168	Intralesional Treatment of Stage III Metastatic Melanoma Patients with L19â€“IL2 Results in Sustained Clinical and Systemic Immunologic Responses. Cancer Immunology Research, 2014, 2, 668-678.	1.6	81
169	Multicenter phase II trial of the histone deacetylase inhibitor pyridylmethyl-N-{4-[(2-aminophenyl)-carbamoyl]-benzyl}-carbamate in pretreated metastatic melanoma. Melanoma Research, 2008, 18, 274-278.	0.6	80
170	Acral lentiginous melanoma: a skin cancer with unfavourable prognostic features. A study of the German central malignant melanoma registry (CMMR) in 2050 patients. British Journal of Dermatology, 2018, 178, 443-451.	1.4	78
171	Antitumor Activities of Interferon Alpha, Beta, and Gamma and their Combinations on Human Melanoma Cells In Vitro: Changes of Proliferation, Melanin Synthesis, and Immunophenotype. Journal of Investigative Dermatology, 1990, 95, S231-S237.	0.3	77
172	Randomized Dose-Escalation Study Evaluating Peginterferon Alfa-2a in Patients With Metastatic Malignant Melanoma. Journal of Clinical Oncology, 2006, 24, 1188-1194.	0.8	77
173	Suppression of Casein Kinase 1Î± in Melanoma Cells Induces a Switch in Î²-Catenin Signaling to Promote Metastasis. Cancer Research, 2010, 70, 6999-7009.	0.4	77
174	â€œFunctionalâ€•Surgery in Subungual Melanoma. Dermatologic Surgery, 2003, 29, 366-374.	0.4	76
175	Effect of Sunscreen and Clothing on the Number of Melanocytic Nevi in 1,812 German Children Attending Day Care. American Journal of Epidemiology, 2005, 161, 620-627.	1.6	76
176	Efficacy of Low-Dose Interferon Î±2a 18 Versus 60 Months of Treatment in Patients With Primary Melanoma of â‰¥ 1.5 mm Tumor Thickness: Results of a Randomized Phase III DeCOG Trial. Journal of Clinical Oncology, 2010, 28, 841-846.	0.8	76
177	Lymph node micrometastases of cutaneous melanoma: Increased sensitivity of molecular diagnosis in comparison to immunohistochemistry. , 1998, 79, 318-323.		75
178	Risk factors of incident melanocytic nevi: A longitudinal study in a cohort of 1,232 young German children. International Journal of Cancer, 2005, 115, 121-126.	2.3	75
179	Generation of Multiple Stable Dermcidin-Derived Antimicrobial Peptides in Sweat of Different Body Sites. Journal of Investigative Dermatology, 2006, 126, 354-365.	0.3	75
180	Adverse events associated with encorafenib plus binimetinib in the COLUMBUS study: incidence, courseÂand management. European Journal of Cancer, 2019, 119, 97-106.	1.3	75

#	Article	IF	Citations
181	Extreme UV Exposure of Professional Cyclists. Dermatology, 2000, 201, 44-45.	0.9	74
182	Growth Control of Melanoma Cells and Melanocytes by Cytokines. Recent Results in Cancer Research, 1995, 139, 169-182.	1.8	74
183	Conventional histology vs. three-dimensional histology in lentigo maligna melanoma. British Journal of Dermatology, 2006, 154, 453-459.	1.4	73
184	Awareness and early detection of cutaneous melanoma: an analysis of factors related to delay in treatment. British Journal of Dermatology, 1999, 141, 783-787.	1.4	72
185	Intralesional rituximab for cutaneous B-cell lymphoma. British Journal of Dermatology, 2001, 144, 1239-1243.	1.4	71
186	Health-related quality of life impact in a randomised phase III study of the combination of dabrafenib and trametinib versus dabrafenib monotherapy in patients with BRAF V600 metastatic melanoma. European Journal of Cancer, 2015, 51, 833-840.	1.3	71
187	The Farnesyl Transferase Inhibitor Lonafarnib Inhibits mTOR Signaling and Enforces Sorafenib-Induced Apoptosis in Melanoma Cells. Journal of Investigative Dermatology, 2011, 131, 468-479.	0.3	69
188	MAPK pathway in melanoma part IIâ€"secondary and adaptive resistance mechanisms to BRAF inhibition. European Journal of Cancer, 2017, 73, 93-101.	1.3	69
189	PI3K Pathway Inhibition Achieves Potent Antitumor Activity in Melanoma Brain MetastasesIn VitroandIn Vivo. Clinical Cancer Research, 2016, 22, 5818-5828.	3.2	68
190	Dermatoscopy Turns Histopathologist's Attention to the Suspicious Area in Melanocytic Lesions. Archives of Dermatology, 2001, 137, 1338-40.	1.7	67
191	Evidence-based and interdisciplinary consensus-based German guidelines: systemic medical treatment of melanoma in the adjuvant and palliative setting. Melanoma Research, 2008, 18, 152-160.	0.6	66
192	Highâ€sensitivity HLA class I peptidome analysis enables a precise definition of peptide motifs and the identification of peptides from cell lines and patientsâ€™ sera. Proteomics, 2016, 16, 1570-1580.	1.3	64
193	Interferons in dermatology. Journal of the American Academy of Dermatology, 1989, 20, 650-656.	0.6	63
194	Cutaneous melanoma in the elderly: epidemiology, prognosis and treatment. Melanoma Research, 2010, 20, 163-170.	0.6	63
195	S3â€Guideline â€œDiagnosis, therapy and followâ€up of melanomaâ€•â€“ short version. JDDG - Journal of the German Society of Dermatology, 2013, 11, 563-602.	0.4	63
196	Wnt-signaling enhances neural crest migration of melanoma cells and induces an invasive phenotype. Molecular Cancer, 2018, 17, 59.	7.9	63
197	Five-year outcomes from a phase 3 METRIC study in patients with BRAF V600ÂE/Kâ€“mutant advanced or metastatic melanoma. European Journal of Cancer, 2019, 109, 61-69.	1.3	63
198	Large Randomized Study of Thymosin Î± 1, Interferon Alfa, or Both in Combination With Dacarbazine in Patients With Metastatic Melanoma. Journal of Clinical Oncology, 2010, 28, 1780-1787.	0.8	62

#	Article	IF	Citations
199	Safety and efficacy of nivolumab in patients with rare melanoma subtypes who progressed on or after ipilimumab treatment: a single-arm, open-label, phase II study (CheckMate 172). European Journal of Cancer, 2019, 119, 168-178.	1.3	61
200	The Dermatoscopic Pattern of Clear-Cell Acanthoma Resembles Psoriasis vulgaris. Dermatology, 2001, 203, 50-52.	0.9	60
201	Mucosal melanomas of the head and neck. Melanoma Research, 2011, 21, 475-482.	0.6	59
202	Overall and site-specific risk of malignant melanoma associated with nevus counts at different body sites: A multicenter case-control study of the german central malignant-melanoma registry. International Journal of Cancer, 1995, 62, 393-397.	2.3	58
203	The stepwise twoâ€photon excited melanin fluorescence is a unique diagnostic tool for the detection of malignant transformation in melanocytes. Pigment Cell and Melanoma Research, 2011, 24, 438-445.	1.5	58
204	Value of the clinical history for different users of dermoscopy compared with results of digital image analysis. Journal of the European Academy of Dermatology and Venereology, 2004, 18, 665-669.	1.3	57
205	Processing of Laminin Î± Chains Generates Peptides Involved in Wound Healing and Host Defense. Journal of Innate Immunity, 2014, 6, 467-484.	1.8	57
206	S3 guideline for actinic keratosis and cutaneous squamous cell carcinoma â€“ short version, part 1: diagnosis, interventions for actinic keratoses, care structures and qualityâ€ofâ€care indicators. JDDG - Journal of the German Society of Dermatology, 2020, 18, 275-294.	0.4	57
207	Open-label, multicenter, single-arm phase II DeCOG-study of ipilimumab in pretreated patients with different subtypes of metastatic melanoma. Journal of Translational Medicine, 2015, 13, 351.	1.8	56
208	Tumor microenvironment-derived S100A8/A9 is a novel prognostic biomarker for advanced melanoma patients and during immunotherapy with anti-PD-1 antibodies. , 2019, 7, 343.		56
209	Dermoscopy of Tungiasis. Archives of Dermatology, 2004, 140, 761-3.	1.7	55
210	MDM2, MDM4 and EGFR Amplifications and Hyperprogression in Metastatic Acral and Mucosal Melanoma. Cancers, 2020, 12, 540.	1.7	55
211	Combined immunotherapy with nivolumab and ipilimumab with and without local therapy in patients with melanoma brain metastasis: a DeCOG* study in 380 patients. , 2020, 8, e000333.		55
212	Serum S100B, Lactate Dehydrogenase and Brain Metastasis Are Prognostic Factors in Patients with Distant Melanoma Metastasis and Systemic Therapy. PLoS ONE, 2013, 8, e81624.	1.1	54
213	Proportions of blood-borne VÎ´1+ and VÎ´2+ T-cells are associated with overall survival of melanoma patients treated with ipilimumab. European Journal of Cancer, 2016, 64, 116-126.	1.3	54
214	Treatment of Psoriasis with Interleukin-10. Journal of Investigative Dermatology, 1998, 111, 1235-1236.	0.3	53
215	Truncation of Activated Leukocyte Cell Adhesion Molecule: A Gateway to Melanoma Metastasis. Journal of Investigative Dermatology, 2004, 122, 1293-1301.	0.3	53
216	Morphoea is neither associated with features of Borrelia burgdorferi infection, nor is this agent detectable in lesional skin by polymerase chain reaction. British Journal of Dermatology, 2000, 143, 780-785.	1.4	52

#	Article	IF	Citations
217	Agreement between Self-Assessment of Melanocytic Nevi by Patients and Dermatologic Examination. American Journal of Epidemiology, 2000, 151, 72-77.	1.6	52
218	Impact of Ulceration in Stages I to III Cutaneous Melanoma As Staged by the American Joint Committee on Cancer Staging System: An Analysis of the German Central Malignant Melanoma Registry. Journal of Clinical Oncology, 2004, 22, 4376-4383.	0.8	52
219	Clinical presentation and management of dermatological toxicities of epidermal growth factor receptor inhibitors. International Journal of Dermatology, 2011, 50, 129-146.	0.5	52
220	Open label randomized study comparing 3â€ƒmonths vs. 6â€ƒmonths treatment of actinic keratoses with 3% diclofenac in 2.5% hyaluronic acid gel: a trial of the German Dermatologic Cooperative Oncology Group. Journal of the European Academy of Dermatology and Venereology, 2012, 26, 48-53.	1.3	52
221	Quantitative Measurement of Melanoma Spread in Sentinel Lymph Nodes and Survival. PLoS Medicine, 2014, 11, e1001604.	3.9	52
222	Vemurafenib. Recent Results in Cancer Research, 2018, 211, 77-89.	1.8	52
223	High Prevalence of Seborrhoeic Dermatitis on the Face and Scalp in Mountain Guides. Dermatology, 2000, 201, 146-147.	0.9	51
224	Interventional study in 1,232 young German children to prevent the development of melanocytic nevi failed to change sun exposure and sun protective behavior. International Journal of Cancer, 2005, 116, 755-761.	2.3	51
225	Survival after intratumoral interleukin-2 treatment of 72 melanoma patients and response upon the first chemotherapy during follow-up. Cancer Immunology, Immunotherapy, 2011, 60, 487-493.	2.0	51
226	Diagnosis and treatment of Merkel cell carcinoma: European consensus-based interdisciplinary guideline â€“ Update 2022. European Journal of Cancer, 2022, 171, 203-231.	1.3	51
227	Effects of Interferons on Cultured Human Melanocytes In Vitro: Interferon-Beta but Not -Alpha or -Gamma Inhibit Proliferation and All Interferons Significantly Modulate the Cell Phenotype. Journal of Investigative Dermatology, 1991, 97, 364-372.	0.3	50
228	Significance of serum protein S100 levels in screening for melanoma metastasis: does protein S100 enable early detection of melanoma recurrence?. Melanoma Research, 2000, 10, 451-459.	0.6	50
229	Costs of the detection of metastases and follow-up examinations in cutaneous melanoma. Melanoma Research, 2009, 19, 50-57.	0.6	50
230	Brief S2k guidelines â€“ Cutaneous squamous cell carcinoma. JDDG - Journal of the German Society of Dermatology, 2013, 11, 37-45.	0.4	50
231	Detection of melanoma cells in sentinel lymph nodes, bone marrow and peripheral blood by a reverse transcription-polymerase chain reaction assay in patients with primary cutaneous melanoma: association with Breslow's tumour thickness. British Journal of Dermatology, 2001, 145, 195-202.	1.4	49
232	Melanoma of the ear: prognostic factors and surgical strategies. British Journal of Dermatology, 2006, 154, 310-318.	1.4	49
233	Time trends in incidence and mortality of cutaneous melanoma in Germany. Journal of the European Academy of Dermatology and Venereology, 2019, 33, 1272-1280.	1.3	49
234	Epidemiology of cutaneous melanoma and keratinocyte cancer in white populations 1943â€“2036. European Journal of Cancer, 2021, 152, 18-25.	1.3	49

#	Article	IF	Citations
235	A case of classical mycosis fungoides associated with human T-cell lymphotropic virus type I. British Journal of Dermatology, 1991, 124, 198-202.	1.4	48
236	The dermoscopic classification of atypical melanocytic naevi (Clark naevi) is useful to discriminate benign from malignant melanocytic lesions. British Journal of Dermatology, 2003, 149, 1159-1164.	1.4	48
237	Problems in defining cutoff points of continuous prognostic factors: Example of tumor thickness in primary cutaneous melanoma. Journal of Clinical Epidemiology, 1997, 50, 1201-1210.	2.4	47
238	Detection of dermcidin-derived peptides in sweat by ProteinChipÂ® Technology. Journal of Immunological Methods, 2002, 270, 53-62.	0.6	47
239	Improvement of overall survival of patients with cutaneous melanoma in Germany, 1976â€“2001. Cancer, 2007, 109, 1174-1182.	2.0	47
240	Functional and symptom impact of trametinib versus chemotherapy in BRAF V600E advanced or metastatic melanoma: quality-of-life analyses of the METRIC study. Annals of Oncology, 2014, 25, 700-706.	0.6	47
241	Bacillus subtilis spore film dosimeters in personal dosimetry for occupational solar ultraviolet exposure. International Archives of Occupational and Environmental Health, 2000, 73, 575-580.	1.1	46
242	Dose-intensified bi-weekly temozolomide in patients with asymptomatic brain metastases from malignant melanoma: a phase II DeCOG/ADO study. Annals of Oncology, 2006, 17, 1592-1597.	0.6	46
243	Brief S2k guidelines â€“ Basal cell carcinoma of the skin. JDDG - Journal of the German Society of Dermatology, 2013, 11, 10-15.	0.4	46
244	18F-FDG-PET detects complete response to PD1-therapy in melanoma patients two weeks after therapy start. European Journal of Nuclear Medicine and Molecular Imaging, 2018, 45, 95-101.	3.3	46
245	Cancer immunotherapy is accompanied by distinct metabolic patterns in primary and secondary lymphoid organs observed by non-invasive in vivo ¹⁸F-FDG-PET. Theranostics, 2020, 10, 925-937.	4.6	46
246	Is detection of melanoma metastasis during surveillance in an early phase of development associated with a survival benefit?. Melanoma Research, 2010, 20, 240-246.	0.6	46
247	Non-AIDS Associated Kaposi's Sarcoma: Clinical Features and Treatment Outcome. PLoS ONE, 2011, 6, e18397.	1.1	46
248	Chemotherapy and chemoimmunotherapy in disseminated malignant melanoma. Melanoma Research, 1993, 3, 291-9.	0.6	46
249	Personal UV Dosimetry by Bacillus subtilis Spore Films. Dermatology, 2000, 200, 1-5.	0.9	45
250	Clinical risk factors and prognostic significance of local recurrence in cutaneous melanoma. British Journal of Dermatology, 2004, 151, 397-406.	1.4	45
251	Sentinel Lymph Node Dissection in Primary Melanoma Reduces Subsequent Regional Lymph Node Metastasis as Well as Distant Metastasis After Nodal Involvement. Annals of Surgical Oncology, 2010, 17, 129-137.	0.7	45
252	443 paediatric cases of malignant melanoma registered with the German Central Malignant Melanoma Registry between 1983 and 2011. European Journal of Cancer, 2015, 51, 861-868.	1.3	45

#	Article	IF	Citations
253	A Nexus Consisting of Beta-Catenin and Stat3 Attenuates BRAF Inhibitor Efficacy and Mediates Acquired Resistance to Vemurafenib. EBioMedicine, 2016, 8, 132-149.	2.7	44
254	CT imaging of bone and bone marrow infiltration in malignant melanomaâ€"Challenges and limitations for clinical staging in comparison to 18FDG-PET/CT. European Journal of Radiology, 2016, 85, 732-738.	1.2	43
255	Oral hairy leukoplakia in 71 HIV-seropositive patients: Clinical symptoms, relation to immunologic status, and prognostic significance. Journal of the American Academy of Dermatology, 1996, 35, 928-934.	0.6	42
256	Short German guidelines: Merkel cell carcinoma. JDDG - Journal of the German Society of Dermatology, 2008, 6, S15-S16.	0.4	42
257	Survival According to BRAF-V600 Tumor Mutations â€“ An Analysis of 437 Patients with Primary Melanoma. PLoS ONE, 2014, 9, e86194.	1.1	42
258	YB-1 Expression and Phosphorylation Regulate Tumorigenicity and Invasiveness in Melanoma by Influencing EMT. Molecular Cancer Research, 2018, 16, 1149-1160.	1.5	42
259	Professional risk for skin cancer development in male mountain guides â€“ a crossâ€sectional study. Journal of the European Academy of Dermatology and Venereology, 2010, 24, 797-804.	1.3	41
260	Merkel cell carcinoma: Epidemiology, pathogenesis, diagnosis and therapy. Reviews in Endocrine and Metabolic Disorders, 2017, 18, 517-532.	2.6	41
261	Improvement of overall survival in stage IV melanoma patients during 2011â€“2014: analysis of real-world data in 441 patients of the German Central Malignant Melanoma Registry (CMMR). Journal of Cancer Research and Clinical Oncology, 2017, 143, 533-540.	1.2	41
262	Increased sensitivity for the detection of malignant melanoma cells in peripheral blood using an improved protocol for reverse transcription?polymerase chain reaction. British Journal of Dermatology, 1999, 141, 37-43.	1.4	40
263	Should adjuvant radiotherapy be recommended following resection of regional lymph node metastases of malignant melanomas?. British Journal of Dermatology, 2001, 144, 66-70.	1.4	40
264	Radiation recall dermatitis and radiation pneumonitis during treatment with vemurafenib. Melanoma Research, 2014, 24, 512-516.	0.6	40
265	Immune checkpoint inhibition therapy for advanced skin cancer in patients with concomitant hematological malignancy: a retrospective multicenter DeCOG study of 84 patients. , 2020, 8, e000897.		40
266	Prognosis of Patients With Stage III Melanoma According to American Joint Committee on Cancer Version 8: A Reassessment on the Basis of 3 Independent Stage III Melanoma Cohorts. Journal of Clinical Oncology, 2020, 38, 2543-2551.	0.8	40
267	COMBI-d: A randomized, double-blinded, Phase III study comparing the combination of dabrafenib and trametinib to dabrafenib and trametinib placebo as first-line therapy in patients (pts) with unresectable or metastatic BRAF^{V600E/K}mutation-positive cutaneous melanoma. Journal of Clinical Oncology, 2014, 32, 9011-9011.	0.8	40
268	Fibroblast growth factor-2 but not Mel-CAM and/or beta3 integrin promotes progression of melanocytes to melanoma. Experimental Dermatology, 2003, 12, 296-306.	1.4	39
269	Short German guidelines: Squamous cell carcinoma. JDDG - Journal of the German Society of Dermatology, 2008, 6, S5-S8.	0.4	39
270	Adjuvant therapy with pegylated interferon alfa-2b (36months) versus low-dose interferon alfa-2b (18months) in melanoma patients without macrometastatic nodes: An open-label, randomised, phase 3 European Association for Dermato-Oncology (EADO) study. European Journal of Cancer, 2013, 49, 166-174.	1.3	39

#	Article	IF	Citations
271	Overall survival at 5 years of follow-up in a phase III trial comparing ipilimumab 10 mg/kg with 3 mg/kg in patients with advanced melanoma. , 2020, 8, e000391.		39
272	S3 guideline for actinic keratosis and cutaneous squamous cell carcinoma (cSCC) â€“ short version, part 2: epidemiology, surgical and systemic treatment of cSCC, followâ€up, prevention and occupational disease. JDDG - Journal of the German Society of Dermatology, 2020, 18, 400-413.	0.4	39
273	Update of progression-free survival (PFS) and correlative biomarker analysis from coBRIM: Phase III study of cobimetinib (cobi) plus vemurafenib (vem) in advanced BRAF-mutated melanoma.. Journal of Clinical Oncology, 2015, 33, 9006-9006.	0.8	39
274	A fluorometric rapid microassay to identify anti-proliferative compounds for human melanoma cells in vitro. Melanoma Research, 1991, 1, 91-96.	0.6	38
275	Epigenetic Impacts of Ascorbate on Human Metastatic Melanoma Cells. Frontiers in Oncology, 2014, 4, 227.	1.3	38
276	Severe hepatitis under combined immunotherapy: ResolutionÂunder corticosteroids plus anti-thymocyte immunoglobulins. European Journal of Cancer, 2017, 81, 203-205.	1.3	38
277	Influence of 18F-FDG PET/CT on therapy management in patients with stage III/IV malignant melanoma. European Journal of Nuclear Medicine and Molecular Imaging, 2016, 43, 482-488.	3.3	37
278	Access to innovative medicines for metastatic melanoma worldwide: Melanoma World Society and European Association of Dermato-oncology survey in 34 countries. European Journal of Cancer, 2018, 104, 201-209.	1.3	37
279	Adjuvant pembrolizumab versus placebo in resected stage III melanoma (EORTC 1325-MG/KEYNOTE-054): health-related quality-of-life results from a double-blind, randomised, controlled, phase 3 trial. Lancet Oncology, The, 2021, 22, 655-664.	5.1	37
280	Interlaboratory Evaluation of a New Reverse Transcriptase Polymerase Chain Reactionâ€“Based Enzyme-Linked Immunosorbent Assay for the Detection of Circulating Melanoma Cells: A Multicenter Study of the Dermatologic Cooperative Oncology Group. Journal of Clinical Oncology, 2001, 19, 1723-1727.	0.8	36
281	Exclusion ofBRAFV599E as a melanoma susceptibility mutation. International Journal of Cancer, 2003, 106, 78-80.	2.3	36
282	Imiquimod in the treatment of extensive recurrent lentigo maligna. Journal of the American Academy of Dermatology, 2005, 52, S51-S52.	0.6	36
283	Clinical course and prognostic factors of Merkel cell carcinoma of the skin. British Journal of Dermatology, 2009, 161, 90-94.	1.4	36
284	Sex differences in survival of cutaneous melanoma are age dependent. Melanoma Research, 2011, 21, 244-252.	0.6	36
285	Circulating CD4+ T Cells That Produce IL4 or IL17 When Stimulated by Melan-A but Not by NY-ESO-1 Have Negative Impacts on Survival of Patients with Stage IV Melanoma. Clinical Cancer Research, 2014, 20, 4390-4399.	3.2	36
286	BRAF Inhibitors Amplify the Proapoptotic Activity of MEK Inhibitors by Inducing ER Stress in NRAS-Mutant Melanoma. Clinical Cancer Research, 2017, 23, 6203-6214.	3.2	36
287	Clinical validation of a prognostic 11-gene expression profiling score in prospectively collected FFPE tissue of patients with AJCC v8 stage II cutaneous melanoma. European Journal of Cancer, 2020, 125, 38-45.	1.3	36
288	Pimasertib Versus Dacarbazine in Patients With Unresectable NRAS-Mutated Cutaneous Melanoma: Phase II, Randomized, Controlled Trial with Crossover. Cancers, 2020, 12, 1727.	1.7	36

#	Article	IF	Citations
289	Targeting tumor-resident mast cells for effective anti-melanoma immune responses. JCI Insight, 2019, 4, .	2.3	36
290	Incomplete Expression of the Tyrosinase Gene Family (Tyrosinase, TRP-1, and TRP-2) in Human Malignant Melanoma Cells In Vitro. Pigment Cell & Melanoma Research, 1995, 8, 307-313.	4.0	35
291	Short German guidelines: Basal cell carcinoma. JDDG - Journal of the German Society of Dermatology, 2008, 6, S2-S4.	0.4	35
292	Efficacy of PD-1â€“based immunotherapy after radiologic progression on targeted therapy in stage IV melanoma. European Journal of Cancer, 2019, 116, 207-215.	1.3	35
293	Distinct Clinicopathological and Prognostic Features of Thin Nodular Primary Melanomas: An International Study from 17 Centers. Journal of the National Cancer Institute, 2019, 111, 1314-1322.	3.0	35
294	First-line therapy-stratified survival in BRAF-mutant melanoma: a retrospective multicenter analysis. Cancer Immunology, Immunotherapy, 2019, 68, 765-772.	2.0	35
295	Local interventions for actinic keratosis in organ transplant recipients: a systematic review. British Journal of Dermatology, 2019, 180, 43-50.	1.4	35
296	Elective lymph node dissection in primary malignant melanoma. Melanoma Research, 1995, 5, 189-194.	0.6	34
297	Advanced cutaneous squamous cell carcinoma: real world data of patient profiles and treatment patterns. Journal of the European Academy of Dermatology and Venereology, 2019, 33, 44-51.	1.3	34
298	Disulfiram as a Therapeutic Agent for Metastatic Malignant Melanomaâ€”Old Myth or New Logos?. Cancers, 2020, 12, 3538.	1.7	34
299	Polymorphisms of the BRAF gene predispose males to malignant melanoma. Journal of Carcinogenesis, 2003, 2, 7.	2.5	34
300	Staphylococcus aureus in Atopic Dermatitis and in Nonatopic Dermatitis. International Journal of Dermatology, 1990, 29, 579-582.	0.5	33
301	Investigation of oestrogen receptors, sex steroids and soluble adhesion molecules in the progression of malignant melanoma. Melanoma Research, 1997, 7, 197-208.	0.6	33
302	Prospective Randomized Multicenter Adjuvant Dermatologic Cooperative Oncology Group Trial of Low-Dose Interferon Alfa-2b With or Without a Modified High-Dose Interferon Alfa-2b Induction Phase in Patients With Lymph Nodeâ€“Negative Melanoma. Journal of Clinical Oncology, 2009, 27, 3496-3502.	0.8	33
303	Proliferative Activity, Chromosomal Aberrations, and Tumor-Specific Mutations in the Differential Diagnosis between Blue Nevi and Melanoma. American Journal of Pathology, 2013, 182, 640-645.	1.9	33
304	The ROS â€induced cytotoxicity of ascorbate is attenuated by hypoxia and HIF â€1alpha in the NCI 60 cancer cell lines. Journal of Cellular and Molecular Medicine, 2014, 18, 530-541.	1.6	33
305	Establishing High Dimensional Immune Signatures from Peripheral Blood via Mass Cytometry in a Discovery Cohort of Stage IV Melanoma Patients. Journal of Immunology, 2017, 198, 927-936.	0.4	33
306	Eighth American Joint Committee on Cancer (AJCC) melanoma classification: Let us reconsider stage III. European Journal of Cancer, 2018, 91, 168-170.	1.3	33

#	Article	IF	Citations
307	Molecular genetics of cutaneous squamous cell carcinoma: perspective for treatment strategies. Journal of the European Academy of Dermatology and Venereology, 2020, 34, 932-941.	1.3	33
308	Production of Cytokines by Human Melanoma Cells and Melanocytes. Recent Results in Cancer Research, 1995, 139, 155-168.	1.8	33
309	Paracrine and autocrine regulation of human melanocyte and melanoma cell growth by transforming growth factor beta in vitro. Anticancer Research, 1994, 14, 2565-71.	0.5	33
310	Prognosis of Patients With Primary Melanoma Stage I and II According to American Joint Committee on Cancer Version 8 Validated in Two Independent Cohorts: Implications for Adjuvant Treatment. Journal of Clinical Oncology, 2022, 40, 3741-3749.	0.8	33
311	Nodular Scabies Detected by Computed Dermatoscopy. Dermatology, 2001, 203, 190-191.	0.9	32
312	Dacarbazine with or without oblimersen (a Bcl-2 antisense oligonucleotide) in chemotherapy-naive patients with advanced melanoma and lowâ€“normal serum lactate dehydrogenase. Melanoma Research, 2014, 24, 237-243.	0.6	32
313	Raman spectroscopy as an analytical tool for melanoma research. Clinical and Experimental Dermatology, 2014, 39, 636-645.	0.6	32
314	More than 5000 patients with metastatic melanoma in Europe per year do not have access to recommended first-line innovative treatments. European Journal of Cancer, 2017, 75, 313-322.	1.3	32
315	A phase II study of the L19IL2 immunocytokine in combination with dacarbazine in advanced metastatic melanoma patients. Cancer Immunology, Immunotherapy, 2019, 68, 1547-1559.	2.0	32
316	Genomic Features of Exceptional Response in Vemurafenib Â± Cobimetinibâ€“treated Patients with BRAFV600-mutated Metastatic Melanoma. Clinical Cancer Research, 2019, 25, 3239-3246.	3.2	32
317	Cytokines in human melanoma cells. Melanoma Research, 1993, 3, 425-434.	0.6	31
318	Application of Argon Plasma Coagulation in Skin Surgery. Dermatology, 1998, 197, 152-157.	0.9	31
319	Blue Light Phototherapy of Neonatal Jaundice Does Not Increase the Risk for Melanocytic Nevus Development. Archives of Dermatology, 2004, 140, 493-4.	1.7	31
320	Efficacy and safety of follow-up field treatment of actinic keratosis with ingenol mebutate 0Â·015% gel: a randomized, controlled 12-month study. British Journal of Dermatology, 2016, 174, 505-513.	1.4	31
321	Open-label, multicentre safety study of vemurafenib inÂ3219 patients with BRAF V600 mutation-positive metastatic melanoma: 2-year follow-up data and long-term responders' analysis. European Journal of Cancer, 2017, 79, 176-184.	1.3	31
322	Change of Epidemiological Characteristics of Malignant Melanoma during the Years 1962â€“1972 and 1983â€“1986 in the Federal Republic of Germany. Dermatology, 1989, 178, 131-135.	0.9	30
323	Genetically Determined Coincidence of Kaposi Sarcoma and Psoriasis in an HIV-Negative Patient After Prednisolone Treatment.. International Journal of Dermatology, 1991, 30, 114-120.	0.5	30
324	Vemurafenib. Recent Results in Cancer Research, 2014, 201, 215-225.	1.8	30

#	Article	IF	Citations
325	The many unanswered questions related to the German skin cancer screening programme. European Journal of Cancer, 2016, 64, 83-88.	1.3	30
326	Distinct Mutation Patterns Reveal Melanoma Subtypes and Influence Immunotherapy Response in Advanced Melanoma Patients. Cancers, 2020, 12, 2359.	1.7	30
327	Five-year overall survival (OS) in COLUMBUS: A randomized phase 3 trial of encorafenib plus binimetinib versus vemurafenib or encorafenib in patients (pts) with BRAF V600-mutant melanoma.. Journal of Clinical Oncology, 2021, 39, 9507-9507.	0.8	30
328	Production and characterization of amplified tumor-derived cRNA libraries to be used as vaccines against metastatic melanomas. Genetic Vaccines and Therapy, 2005, 3, 6.	1.5	29
329	Melanoma of unknown primary is correctly classified by the AJCC melanoma classification from 2009. Melanoma Research, 2011, 21, 228-234.	0.6	29
330	Recurrent nodules in a periauricular plaqueâ€type blue nevus with fatal outcome. Journal of Cutaneous Pathology, 2012, 39, 1088-1093.	0.7	29
331	S3â€Leitlinie Diagnostik, Therapie und Nachsorge des Melanoms â€“ Update 2015/2016, Kurzversion 2.0. JDDG - Journal of the German Society of Dermatology, 2017, 15, e1-e41.	0.4	29
332	Results of COLUMBUS Part 2: A phase 3 trial of encorafenib (ENCO) plus binimetinib (BINI) versus ENCO in BRAF-mutant melanoma. Annals of Oncology, 2017, 28, v429-v430.	0.6	29
333	Diffuse PRAME Expression Is Highly Specific for Thin Melanomas in the Distinction from Severely Dysplastic Nevi but Does Not Distinguish Metastasizing from Non-Metastasizing Thin Melanomas. Cancers, 2021, 13, 3864.	1.7	29
334	Management of cutaneous side effects of EGFR inhibitors: recommendations from a German expert panel for the primary treating physician. JDDG - Journal of the German Society of Dermatology, 2011, 9, 195-202.	0.4	28
335	In melanoma, <scp>H</scp>ippo signaling is affected by copy number alterations and <scp>YAP</scp>1 overexpression impairs patient survival. Pigment Cell and Melanoma Research, 2014, 27, 671-673.	1.5	28
336	Diminished levels of the soluble form of <scp>RAGE</scp> are related to poor survival in malignant melanoma. International Journal of Cancer, 2015, 137, 2607-2617.	2.3	28
337	Sentinel Lymph Node Dissection in Head and Neck Melanoma has Prognostic Impact on Disease-Free and Overall Survival. Annals of Surgical Oncology, 2015, 22, 4073-4080.	0.7	28
338	Accurate quantification of T-cells expressing PD-1 in patients on anti-PD-1 immunotherapy. Cancer Immunology, Immunotherapy, 2018, 67, 1845-1851.	2.0	28
339	Chemotherapy after immune checkpoint inhibitor failure in metastatic melanoma: a retrospective multicentre analysis. European Journal of Cancer, 2022, 162, 22-33.	1.3	28
340	Dermoscopic classification of Clarkâ€™s nevi (atypical melanocytic nevi). Clinics in Dermatology, 2002, 20, 255-258.	0.8	27
341	Micrometastasis of a Sentinel Lymph Node in Cutaneous Melanoma Is a Significant Prognostic Factor for Disease-Free Survival, Distant-Metastasis-Free Survival, and Overall Survival. Dermatologic Surgery, 2004, 30, 1319-1328.	0.4	27
342	Variability of Dermoscopic Features of Tungiasis. Archives of Dermatology, 2005, 141, 643-4.	1.7	27

#	Article	IF	Citations
343	Temozolomide plus pegylated interferon alfa-2b as first-line treatment for stage IV melanoma: a multicenter phase II trial of the Dermatologic Cooperative Oncology Group (DeCOG). Annals of Oncology, 2008, 19, 801-806.	0.6	27
344	Topical 3.0% diclofenac in 2.5% hyaluronic acid gel induces regression of cancerous transformation in actinic keratoses. Journal of the European Academy of Dermatology and Venereology, 2010, 24, 258-263.	1.3	27
345	Sorafenib and pegylated interferon-Î±2b in advanced metastatic melanoma: a multicenter phase II DeCOG trial. Annals of Oncology, 2011, 22, 1667-1674.	0.6	27
346	Analysis of BRAF and NRAS Mutation Status in Advanced Melanoma Patients Treated with Anti-CTLA-4 Antibodies: Association with Overall Survival?. PLoS ONE, 2015, 10, e0139438.	1.1	27
347	High GDF-15 Serum Levels Independently Correlate with Poorer Overall Survival of Patients with Tumor-Free Stage III and Unresectable Stage IV Melanoma. Journal of Investigative Dermatology, 2016, 136, 2444-2452.	0.3	27
348	Safety and efficacy of nivolumab in challenging subgroups with advanced melanoma who progressed on or after ipilimumab treatment: A single-arm, open-label, phase II study (CheckMate 172). European Journal of Cancer, 2019, 121, 144-153.	1.3	27
349	Primary results from a randomized (1:1), open-label phase II study of talimogene laherparepvec (T) and ipilimumab (I) vs I alone in unresected stage IIIB- IV melanoma.. Journal of Clinical Oncology, 2017, 35, 9509-9509.	0.8	27
350	Predictors of the Use of Sunscreen in Dermatological Patients in Central Europe. Preventive Medicine, 2000, 31, 134-139.	1.6	26
351	Correlation with digital dermoscopic images can help dermatopathologists to diagnose equivocal skin tumours. British Journal of Dermatology, 2006, 155, 546-551.	1.4	26
352	Short German guidelines: Dermatofibrosarcoma protuberans. JDDG - Journal of the German Society of Dermatology, 2008, 6, S17-8.	0.4	26
353	Histopathological diagnostics of malignant melanoma in accordance with the recent AJCC classification 2009: Review of the literature and recommendations for general practice. JDDG - Journal of the German Society of Dermatology, 2011, 9, 690-699.	0.4	26
354	Prognostic Factors of Melanoma Patients with Satellite or In-Transit Metastasis at the Time of Stage III Diagnosis. PLoS ONE, 2013, 8, e63137.	1.1	26
355	UVA-Irradiation Induces Melanoma Invasion via the Enhanced Warburg Effect. Journal of Investigative Dermatology, 2016, 136, 1866-1875.	0.3	26
356	Pediatric patients with cutaneous melanoma: A European study. Pediatric Blood and Cancer, 2018, 65, e26974.	0.8	26
357	Role of High-Resolution Magnetic Resonance Imaging for Differentiating Melanin-Containing Skin Tumors. Investigative Radiology, 1995, 30, 638-643.	3.5	25
358	Specifically regulated genes in malignant melanoma tissues identified by subtractive hybridization. British Journal of Cancer, 2000, 82, 1149-1157.	2.9	25
359	Prospective evaluation of supportive care with or without CVD chemotherapy as a second-line treatment in advanced melanoma by patientâ€™s choice. Melanoma Research, 2011, 21, 516-523.	0.6	25
360	6- and 8-Prenylnaringenin, Novel Natural Histone Deacetylase Inhibitors Found in Hops, Exert Antitumor Activity on Melanoma Cells. Cellular Physiology and Biochemistry, 2018, 51, 543-556.	1.1	25

#	Article	IF	Citations
361	Adjuvant melanoma therapy with new drugs: should physicians continue to focus on metastatic disease or use it earlier in primary melanoma?. Lancet Oncology, The, 2018, 19, e720-e725.	5.1	25
362	The German Melanoma Registry and Environmental Risk Factors Implied. Recent Results in Cancer Research, 1993, 128, 69-89.	1.8	25
363	Tumour necrosis factors and several interleukins inhibit the growth and modulate the antigen expression of normal human melanocytes in vitro. Archives of Dermatological Research, 1995, 287, 259-265.	1.1	24
364	Melanocytes in nevi and melanomas synthesize basement membrane and basement membrane-like material. An immunohistochemical and electron microscopic study including immunoelectron microscopy. Journal of Cutaneous Pathology, 2000, 27, 67-75.	0.7	24
365	Adjuvant treatment with vindesine in comparison to observation alone in patients with metastasized melanoma after complete metastasectomy: a randomized multicenter trial of the German Dermatologic Cooperative Oncology Group. Melanoma Research, 2008, 18, 353-358.	0.6	24
366	Phenotypic characterization and prognostic impact of circulating Î³Î´ and Î±Î² <scp>T</scp>â€cells in metastatic malignant melanoma. International Journal of Cancer, 2016, 138, 698-704.	2.3	24
367	Serial or Parallel Metastasis of Cutaneous Melanoma? A Study of the German Central Malignant Melanoma Registry. Journal of Investigative Dermatology, 2017, 137, 2570-2577.	0.3	24
368	Patterns of response with talimogene laherparepvec in combination with ipilimumab or ipilimumab alone in metastatic unresectable melanoma. British Journal of Cancer, 2019, 121, 417-420.	2.9	24
369	Evaluation of Long-term Clearance Rates of Interventions for Actinic Keratosis. JAMA Dermatology, 2021, 157, 1066.	2.0	24
370	Efficacy and safety of cobimetinib (C) combined with vemurafenib (V) in patients (pts) with BRAF^{V600} mutationâ€“positive metastatic melanoma: analysis from the 4-year extended follow-up of the phase 3 coBRIM study.. Journal of Clinical Oncology, 2018, 36, 9522-9522.	0.8	24
371	Effects of Interferons and Cytokines on Melanoma Cells. Journal of Investigative Dermatology, 1993, 100, S239-S244.	0.3	23
372	Cutaneous metastatic angiosarcoma with a lethal outcome, following radiotherapy for a cervical carcinoma. British Journal of Dermatology, 1995, 133, 610-614.	1.4	23
373	Direct effects on proliferation, antigen expression and melanin synthesis of cultured normal human melanocytes in response to UVB and UVA light. Photodermatology Photoimmunology and Photomedicine, 2003, 19, 122-127.	0.7	23
374	Is Sentinel Lymph Node Biopsy of Therapeutic Relevance for Melanoma?. Dermatology, 2004, 209, 5-13.	0.9	23
375	Excision guidelines and follow-up strategies in cutaneous melanoma: Facts and controversies. Clinics in Dermatology, 2010, 28, 311-315.	0.8	23
376	CHEK2*1100delC and Risk of Malignant Melanoma: Danish and German Studies and Meta-Analysis. Journal of Investigative Dermatology, 2012, 132, 299-303.	0.3	23
377	Effectiveness and Tolerability of Ipilimumab. Journal of Immunotherapy, 2014, 37, 374-381.	1.2	23
378	Adjuvant treatment with pegylated interferon Î±-2a versus low-dose interferon Î±-2a in patients with high-risk melanoma: a randomized phase III DeCOG trial. Annals of Oncology, 2016, 27, 1625-1632.	0.6	23

#	Article	IF	Citations
379	Non-melanoma skin cancer: new and future synthetic drug treatments. Expert Opinion on Pharmacotherapy, 2017, 18, 689-699.	0.9	23
380	Impact of 18F-FDG-PET/CT on surgical management in patients with advanced melanoma: an outcome based analysis. European Journal of Nuclear Medicine and Molecular Imaging, 2017, 44, 1312-1318.	3.3	23
381	Combined treatment with ipilimumab and intratumoral interleukin-2 in pretreated patients with stage IV melanomaâ€"safety and efficacy in a phase II study. Cancer Immunology, Immunotherapy, 2017, 66, 441-449.	2.0	23
382	Human melanoma cells resistant to MAPK inhibitors can be effectively targeted by inhibition of the p90 ribosomal S6 kinase. Oncotarget, 2017, 8, 35761-35775.	0.8	23
383	Immune Checkpoint Blockade in Advanced Cutaneous Squamous Cell Carcinoma: What Do We Currently Know in 2020?. International Journal of Molecular Sciences, 2020, 21, 9300.	1.8	23
384	A Rational Approach to the Follow-up of Melanoma Patients. Recent Results in Cancer Research, 2002, 160, 205-215.	1.8	23
385	Kaposiâ€™s Sarcoma: A Reevaluation. Recent Results in Cancer Research, 1995, , 275-296.	1.8	23
386	Overall survival in COLUMBUS: A phase 3 trial of encorafenib (ENCO) plus binimetinib (BINI) vs vemurafenib (VEM) or enco in BRAF-mutant melanoma.. Journal of Clinical Oncology, 2018, 36, 9504-9504.	0.8	23
387	Multicenter evaluation of the analytical and clinical performance of the Elecsys Â® S100 immunoassay in patients with malignant melanoma. Clinical Chemistry and Laboratory Medicine, 2005, 43, 557-63.	1.4	22
388	Management of pegylated interferon alpha toxicity in adjuvant therapy of melanoma. Expert Opinion on Biological Therapy, 2012, 12, 1087-1099.	1.4	22
389	S100B and lactate dehydrogenase as response and progression markers during treatment with vemurafenib in patients with advanced melanoma. Melanoma Research, 2013, 23, 396-401.	0.6	22
390	Melanoma Patients with Unknown Primary Site or Nodal Recurrence after Initial Diagnosis Have a Favourable Survival Compared to Those with Synchronous Lymph Node Metastasis and Primary Tumour. PLoS ONE, 2013, 8, e66953.	1.1	22
391	Immunotherapy plus surgery/radiosurgery is associated with favorable survival in patients with melanoma brain metastasis. Immunotherapy, 2019, 11, 297-309.	1.0	22
392	The evolving field of Dermatoâ€•oncology and the role of dermatologists: Position Paper of the EADO, EADV and Task Forces, EDF, IDS, EBDVâ€"UEMS and EORTC Cutaneous Lymphoma Task Force. Journal of the European Academy of Dermatology and Venereology, 2020, 34, 2183-2197.	1.3	22
393	Detection of Micrometastasis in Sentinel Lymph Nodes of Patients with Primary Cutaneous Melanoma. Recent Results in Cancer Research, 2001, 158, 137-146.	1.8	22
394	Effectiveness of Carboplatin and Paclitaxel as First- and Second-Line Treatment in 61 Patients with Metastatic Melanoma. PLoS ONE, 2011, 6, e16882.	1.1	22
395	Primary Localization and Tumor Thickness as Prognostic Factors of Survival in Patients with Mucosal Melanoma. PLoS ONE, 2014, 9, e112535.	1.1	22
396	A rapid and sensitive fluorometric microassay for determining cell mediated cytotoxicity to adherent growing cell lines. Journal of Immunological Methods, 1992, 156, 1-8.	0.6	21

#	Article	IF	Citations
397	Surveillance and Follow-up Examinations in Cutaneous Melanoma. Oncology Research and Treatment, 2003, 26, 241-246.	0.8	21
398	Melanoma staging: Facts and controversies. Clinics in Dermatology, 2010, 28, 275-280.	0.8	21
399	Is there a link between very early changes of primary and secondary lymphoid organs in ¹⁸F-FDG-PET/MRI and treatment response to checkpoint inhibitor therapy?. , 2020, 8, e000656.		21
400	Prolonged survival of 2 years or longer for patients with disseminated melanoma. An analysis of related prognostic factors. Cancer, 1997, 79, 2345-53.	2.0	21
401	Solar UV-Protective Properties of Textiles. Dermatology, 2000, 201, 82-82.	0.9	20
402	Noggin blocks invasive growth of murine B16â€F1 melanoma cells in the optic cup of the chick embryo. International Journal of Cancer, 2008, 122, 526-533.	2.3	20
403	Improved protection of outdoor workers from solar ultraviolet radiation: position statement. Journal of the European Academy of Dermatology and Venereology, 2021, 35, 1278-1284.	1.3	20
404	Epidemiologie des Hautkrebses. , 1997, , 40-56.		20
405	Dose comparison of tropisetron (Navoban) 5 mg and 10 mg orally in the prophylaxis of dacarbazine-induced nausea and emesis. Seminars in Oncology, 1994, 21, 12-6.	0.8	20
406	RNA isolation from human skin tissues for colorimetric differential display. Journal of Proteomics, 1998, 37, 131-135.	2.4	19
407	Extramammary Paget's Disease: Extended Subclinical Growth Detected Using Three-Dimensional Histology in Routine Paraffin Procedure and Course of the Disease. Dermatologic Surgery, 2011, 37, 1417-1426.	0.4	19
408	A randomized, openâ€label clinical trial of tasisulam sodium versus paclitaxel as secondâ€line treatment in patients with metastatic melanoma. Cancer, 2014, 120, 2016-2024.	2.0	19
409	Health-related quality of life impact of cobimetinib in combination with vemurafenib in patients with advanced or metastatic BRAFV600 mutationâ€“positive melanoma. British Journal of Cancer, 2018, 118, 777-784.	2.9	19
410	Fear of cancer progression in patients with stage IA malignant melanoma. European Journal of Cancer Care, 2018, 27, e12901.	0.7	19
411	Adjuvant therapy for cutaneous melanoma: a systematic review and network metaâ€analysis of new therapies. Journal of the European Academy of Dermatology and Venereology, 2020, 34, 956-966.	1.3	19
412	Lack ofp73 mutations and late occurrence ofp73 allelic deletions in melanoma tissues and cell lines. , 1999, 82, 583-586.		18
413	Does Mountaineering Increase the Incidence of Cutaneous Melanoma?. Dermatology, 1999, 199, 201-203.	0.9	18
414	Significant response after treatment with the mTOR inhibitor sirolimus in combination with carboplatin and paclitaxel in metastatic melanoma patients. Journal of the American Academy of Dermatology, 2009, 60, 863-868.	0.6	18

#	Article	IF	Citations
415	Diagnosis of cutaneous tumors with in vivo confocal laser scanning microscopy. JDDG - Journal of the German Society of Dermatology, 2010, 8, 400-410.	0.4	18
416	BRAF-V600 Mutations Have No Prognostic Impact in Stage IV Melanoma Patients Treated with Monochemotherapy. PLoS ONE, 2014, 9, e89218.	1.1	18
417	Patient acceptance and trust in automated computerâ€assisted diagnosis of melanoma with dermatofluoroscopy. JDDG - Journal of the German Society of Dermatology, 2018, 16, 854-859.	0.4	18
418	S1 guidelines for dermatofibrosarcoma protuberans (DFSP) â€“ update 2018. JDDG - Journal of the German Society of Dermatology, 2019, 17, 663-668.	0.4	18
419	Tumour Progression Stage-Dependent Secretion of YB-1 Stimulates Melanoma Cell Migration and Invasion. Cancers, 2020, 12, 2328.	1.7	18
420	Ultraviolet light exposure, pigmentary traits and the development of melanocytic naevi and cutaneous melanoma. A case-control study of the German Central Malignant Melanoma Registry.. Acta Dermato-Venereologica, 1997, 77, 374-378.	0.6	18
421	12-O-Tetradecanoylphorbol-13-Acetate Not Only Modulates Proliferation Rates, But Also Alters Antigen Expression and LAK-Cell Susceptibility of Normal Human Melanocytes In Vitro. Journal of Investigative Dermatology, 1993, 100, 653-659.	0.3	17
422	P53 Mutation and c-fos Overexpression Are Associated With Detection of the Antigen VLA-2 in Human Melanoma Cell Lines. Pigment Cell & Melanoma Research, 1994, 7, 348-353.	4.0	17
423	Seasonal patterns in the diagnosis of cutaneous malignant melanoma: analysis of the data of the German Central Malignant Melanoma Registry. British Journal of Dermatology, 1997, 136, 968-969.	1.4	17
424	Does intensive histopathological workup by serial sectioning increase the detection of lymph node micrometastasis in patients with primary cutaneous melanoma?. Melanoma Research, 2001, 11, 57-63.	0.6	17
425	Monocytic myeloid-derived suppressor cells in advanced melanoma patients. OncoImmunology, 2014, 3, e27845.	2.1	17
426	Diagnostic accuracy of dermatofluoroscopy in cutaneous melanoma detection: results of a prospective multicentre clinical study in 476 pigmented lesions. British Journal of Dermatology, 2018, 179, 478-485.	1.4	17
427	Primary Resistance to PD-1-Based Immunotherapyâ€”A Study in 319 Patients with Stage IV Melanoma. Cancers, 2020, 12, 1027.	1.7	17
428	Polymerase Chain Reaction in the Detection of Circulating Tumour Cells in Peripheral Blood of Melanoma Patients. Recent Results in Cancer Research, 2001, 158, 93-104.	1.8	17
429	Persistent scleredema of Buschke in a diabetic: improvement with high-dose penicillin. British Journal of Dermatology, 1996, 134, 597-598.	1.4	17
430	A phase II multicenter study on the histone deacetylase (HDAC) inhibitor MS-275, comparing two dosage schedules in metastatic melanoma. Journal of Clinical Oncology, 2006, 24, 8044-8044.	0.8	17
431	Efficacy and safety of nivolumab (NIVO) in patients with advanced melanoma (MEL) and poor prognostic factors who progressed on or after ipilimumab (IPI): Results from a phase II study (CheckMate 172).. Journal of Clinical Oncology, 2017, 35, 9524-9524.	0.8	17
432	Cytostatic and Cytotoxic Effects of Recombinant Tumor Necrosis Factor-Î± on Sensitive Human Melanoma Cells In Vitro May Result in Selection of Cells with Enhanced Markers of Malignancy. Journal of Investigative Dermatology, 1990, 95, S223-S230.	0.3	16

#	Article	IF	Citations
433	Hyperkeratosis lenticularis perstans (Flegelâ€™s Disease) â€“ Lack of Response to Treatment with Tacalcitol and Calcipotriol. Dermatology, 2001, 202, 255-258.	0.9	16
434	Comparative analysis of incidence and clinical features of cutaneous malignant melanoma in Crete (Greece) and southern Germany (central Baden-WÃ¼rttemberg). British Journal of Dermatology, 2006, 154, 1123-1127.	1.4	16
435	The Mitochondrial DNA Common Deletion Is Present in Most Basal and Squamous Cell Carcinoma Samples Isolated by Laser Capture Microdissection but Generally at Reduced Rather than Increased Levels. Journal of Investigative Dermatology, 2007, 127, 486-490.	0.3	16
436	Distribution of muscarinic receptor subtype M3 in melanomas and their metastases. Journal of Cutaneous Pathology, 2008, 35, 809-815.	0.7	16
437	Melanocytic nevi. JDDG - Journal of the German Society of Dermatology, 2011, 9, 723-734.	0.4	16
438	S2k Kurzleitlinie - Plattenepithelkarzinom der Haut. JDDG - Journal of the German Society of Dermatology, 2013, 11, 39-47.	0.4	16
439	Increased CCL17 serum levels are associated with improved survival in advanced melanoma. Cancer Immunology, Immunotherapy, 2015, 64, 1075-1082.	2.0	16
440	Intralesional immunotherapy as a strategy to treat melanoma. Expert Opinion on Biological Therapy, 2016, 16, 619-626.	1.4	16
441	Clinical characteristics and outcome of 60 pediatric patients with malignant melanoma registered with the German Pediatric Rare Tumor Registry (STEP). Klinische Padiatrie, 2017, 229, 322-328.	0.2	16
442	Melanoma cells resistant towards MAPK inhibitors exhibit reduced TAp73 expression mediating enhanced sensitivity to platinum-based drugs. Cell Death and Disease, 2018, 9, 930.	2.7	16
443	Peripheral PD-1+CD56+ T-cell frequencies correlate with outcome in stage IV melanoma under PD-1 blockade. PLoS ONE, 2019, 14, e0221301.	1.1	16
444	Prognostic factors in 161 patients with mucosal melanoma: a study of German Central Malignant Melanoma Registry. Journal of the European Academy of Dermatology and Venereology, 2020, 34, 2021-2025.	1.3	16
445	Perspectives of Cytokine Treatment in Malignant Skin Tumors. Recent Results in Cancer Research, 1995, 139, 349-369.	1.8	16
446	Final analysis of DECOG-SLT trial: Survival outcomes of complete lymph node dissection in melanoma patients with positive sentinel node.. Journal of Clinical Oncology, 2018, 36, 9501-9501.	0.8	16
447	Update on overall survival in COLUMBUS: A randomized phase III trial of encorafenib (ENCO) plus binimetinib (BINI) versus vemurafenib (VEM) or ENCO in patients with BRAF V600â€“mutant melanoma.. Journal of Clinical Oncology, 2019, 37, 9512-9512.	0.8	16
448	Treatment of Melanoma. Deutsches Ärzteblatt International, 2008, 105, 845-51.	0.6	16
449	The role of stereotactic radiotherapy in addition to immunotherapy in the management of melanoma brain metastases: results of a systematic review. Radiologia Medica, 2022, 127, 773-783.	4.7	16
450	The New American Joint Committee on Cancer staging system for cutaneous melanoma. Cancer, 2002, 94, 2305-2307.	2.0	15

#	Article	IF	Citations
451	Molecular diagnostics facilitate distinction between lethal and non-lethal subtypes of junctional epidermolysis bullosa: a case report and review of the literature. European Journal of Pediatrics, 2002, 161, 672-679.	1.3	15
452	Risk Estimation for Malignant Transformation of Melanocytic Nevi. Archives of Dermatology, 2004, 140, 127; author reply 127.	1.7	15
453	Epidemiology of Malignant Melanoma in Central Europe: Risk Factors and Prognostic Predictors. Results of the Central Malignant Melanoma Registry of the German Dermatological Society. Pigment Cell & Melanoma Research, 1990, 3, 285-294.	4.0	15
454	Melanoma-specific survival in patients with positive sentinel lymph nodes: Relevance of sentinel tumor burden. European Journal of Cancer, 2019, 123, 83-91.	1.3	15
455	Long-term safety and efficacy of vismodegib in patients with advanced basal cell carcinoma: Final update (30-month) of the pivotal ERIVANCE BCC study.. Journal of Clinical Oncology, 2014, 32, 9013-9013.	0.8	15
456	Alopecia areata Induced by Adjuvant Treatment with Alpha-Interferon in Malignant Melanoma?. Dermatology, 2004, 209, 249-250.	0.9	14
457	Distribution and colocalization of markers for proliferation, invasion, motility and neoangiogenesis in benign melanocytic naevi and malignant melanomas. British Journal of Dermatology, 2005, 153, 1159-1165.	1.4	14
458	Inflammatory nodules around the axilla: an uncommon localization of orf virus infection. Clinical and Experimental Dermatology, 2009, 34, 240-242.	0.6	14
459	MelanozytÃre NÃvi. JDDG - Journal of the German Society of Dermatology, 2011, 9, 723-736.	0.4	14
460	Prognosis of Sentinel Node Staged Patients with Primary Cutaneous Melanoma. PLoS ONE, 2012, 7, e29791.	1.1	14
461	S2k Kurzleitlinie â€“ Basalzellkarzinom der Haut. JDDG - Journal of the German Society of Dermatology, 2013, 11, 11-16.	0.4	14
462	Combined activity of temozolomide and the <scp>mTOR</scp> inhibitor temsirolimus in metastatic melanoma involves DKK1. Experimental Dermatology, 2017, 26, 598-606.	1.4	14
463	Incidence and characteristics of thick second primary melanomas: a study of the German Central Malignant Melanoma Registry. Journal of the European Academy of Dermatology and Venereology, 2019, 33, 63-70.	1.3	14
464	Position statement on classification of basal cell carcinomas. Part 2: EADO proposal for new operational staging system adapted to basal cell carcinomas. Journal of the European Academy of Dermatology and Venereology, 2021, 35, 2149-2153.	1.3	14
465	METRIC phase III study: Efficacy of trametinib (T), a potent and selective MEK inhibitor (MEKi), in progression-free survival (PFS) and overall survival (OS), compared with chemotherapy (C) in patients (pts) with BRAFV600E/K mutant advanced or metastatic melanoma (MM).. Journal of Clinical Oncology, 2012, 30, LBA8509-LBA8509.	0.8	14
466	Update on overall survival in COLUMBUS: A randomized phase III trial of encorafenib (ENCO) plus binimetinib (BINI) versus vemurafenib (VEM) or ENCO in patients with BRAF V600-mutant melanoma.. Journal of Clinical Oncology, 2020, 38, 10012-10012.	0.8	14
467	Increase of melanocytic nevus counts in children during 5 years of follow-up and analysis of associated factors. Archives of Dermatology, 1996, 132, 1473-8.	1.7	14
468	Dermatofibrosarcoma protuberans - An Update. Neues zum Dermatofibrosarkoma protuberans. JDDG - Journal of the German Society of Dermatology, 2004, 2, 661-667.	0.4	13

#	Article	IF	Citations
469	Micrometastasis of a Sentinel Lymph Node in Cutaneous Melanoma Is a Significant Prognostic Factor for Disease-Free Survival, Distant-Metastasis-Free Survival, and Overall Survival. Dermatologic Surgery, 2004, 30, 1319-1328.	0.4	13
470	Melanoma of the Nose: Prognostic Factors, Three-Dimensional Histology, and Surgical Strategies. Laryngoscope, 2006, 116, 1204-1211.	1.1	13
471	Metastatic patterns and metastatic sites in mucosal melanoma: a retrospective study. European Radiology, 2016, 26, 1826-1834.	2.3	13
472	Immunotherapy in managing metastatic melanoma: which treatment when?. Expert Opinion on Biological Therapy, 2017, 17, 1523-1538.	1.4	13
473	An open-label, multicentre safety study of vemurafenib in patients with BRAFV600-mutant metastatic melanoma: final analysis and a validated prognostic scoring system. European Journal of Cancer, 2019, 107, 175-185.	1.3	13
474	A multicentre study of naevusâ€associated melanoma vs. de novo melanoma, tumour thickness and body site differences*. British Journal of Dermatology, 2021, 185, 101-109.	1.4	13
475	Predictive importance of ulceration on the efficacy of adjuvant interferon-a (IFN): An individual patient data (IPD) meta-analysis of 15 randomized trials in more than 7,500 melanoma patients (pts).. Journal of Clinical Oncology, 2014, 32, 9067-9067.	0.8	13
476	Isolation of three stem cell lines from human sacrococcygeal teratomas. Journal of Pathology, 2009, 217, 589-596.	2.1	12
477	Brief S2k guidelines â€“ Dermatofibrosarcoma protuberans. JDDG - Journal of the German Society of Dermatology, 2013, 11, 16-18.	0.4	12
478	Mitotic rate in primary melanoma: interobserver and intraobserver reliability, analyzed using H&E sections and immunohistochemistry. JDDG - Journal of the German Society of Dermatology, 2016, 14, 910-915.	0.4	12
479	Mitoserate beim primÃren Melanom: Interobserverâ€•und Intraobserverâ€Reproduzierbarkeit am HEâ€Schnitt und in der Immunhistologie. JDDG - Journal of the German Society of Dermatology, 2016, 14, 910-916.	0.4	12
480	Melanoma and immunotherapy bridge 2015. Journal of Translational Medicine, 2016, 14, 65.	1.8	12
481	Preferences of German melanoma patients for interferon (IFN) Î±-2b toxicities (the DeCOG â€œGERMELATOX) Tj ETQq1 1 0.784314 rgB Medicine (United States), 2016, 95, e5375.	0.4	12
482	<scp>GSTP</scp>1 does not modify <scp>MC</scp>1R effects on melanoma risk. Experimental Dermatology, 2017, 26, 730-733.	1.4	12
483	The need for psycho-oncological support for melanoma patients. Medicine (United States), 2017, 96, e7987.	0.4	12
484	Imaging characteristics of cardiac metastases in patients with malignant melanoma. Cancer Imaging, 2017, 17, 19.	1.2	12
485	The sentinel lymph node spread determines quantitatively melanoma seeding to non-sentinel lymph nodes and survival. European Journal of Cancer, 2018, 91, 1-10.	1.3	12
486	Targeting Rad51 as a strategy for the treatment of melanoma cells resistant to MAPK pathway inhibition. Cell Death and Disease, 2020, 11, 581.	2.7	12

#	Article	IF	Citations
487	Pitfalls in the characterization of circulating and tissue-resident human Î³Î´ T cells. Journal of Leukocyte Biology, 2020, 107, 1097-1105.	1.5	12
488	Prognostic significance of an 11-gene RNA assay in archival tissue of cutaneous melanoma stage Iâ€“III patients. European Journal of Cancer, 2021, 143, 11-18.	1.3	12
489	Serum S100B and LDH at Baseline and During Therapy Predict the Outcome of Metastatic Melanoma Patients Treated with BRAF Inhibitors. Targeted Oncology, 2021, 16, 197-205.	1.7	12
490	Not all melanomas are created equal: a review and call for more research into nodular melanoma. British Journal of Dermatology, 2021, 185, 700-710.	1.4	12
491	Which melanoma patient carries a BRAF-mutation? A comparison of predictive models. Oncotarget, 2016, 7, 36130-36137.	0.8	12
492	Effects of interferons and cytokines on melanoma cells. Journal of Investigative Dermatology, 1993, 100, 239S-244S.	0.3	12
493	Prothymosin Î±1 modulates lymphokine-activated killer cell activity and IL-2 production by peripheral blood lymphocytes from melanoma patients in vitro. International Journal of Immunopharmacology, 1995, 17, 555-561.	1.1	11
494	Lack of activity of betulin-based Oleogel-S10 in the treatment of actinic keratoses: a randomized, multicentre, placebo-controlled double-blind phase II trial. British Journal of Dermatology, 2015, 172, 926-932.	1.4	11
495	Genomics of Immunotherapy-Associated Hyperprogressorsâ€”Letter. Clinical Cancer Research, 2017, 23, 6374-6375.	3.2	11
496	Lack of survival benefit in sentinel lymph nodeâ€positive melanoma with immediate complete lymphadenectomy â€“ a review. JDDG - Journal of the German Society of Dermatology, 2019, 17, 7-13.	0.4	11
497	A Systematic Review and Meta-Analysis of Interventions for Actinic Keratosis from Post-Marketing Surveillance Trials. Journal of Clinical Medicine, 2020, 9, 2253.	1.0	11
498	The EORTC-DeCOG nomogram adequately predicts outcomes of patients with sentinel nodeâ€“positive melanoma without the need for completion lymph node dissection. European Journal of Cancer, 2020, 134, 9-18.	1.3	11
499	Case Report: Combined CDK4/6 and MEK Inhibition in Refractory CDKN2A and NRAS Mutant Melanoma. Frontiers in Oncology, 2021, 11, 643156.	1.3	11
500	Pretreatment metastatic growth rate determines clinical outcome of advanced melanoma patients treated with anti-PD-1 antibodies: a multicenter cohort study. , 2021, 9, e002350.		11
501	Cutaneous melanoma attributable to UVR exposure in Denmark and Germany. European Journal of Cancer, 2021, 159, 98-104.	1.3	11
502	Association between Immune-Related Adverse Events and Survival in 319 Stage IV Melanoma Patients Treated with PD-1-Based Immunotherapy: An Approach Based on Clinical Chemistry. Cancers, 2021, 13, 6141.	1.7	11
503	Isotopic Response of Graft Versus Host Disease Following Herpes Zoster Infection: Case Report and Review of the Literature. Acta Dermato-Venereologica, 2012, 92, 383-384.	0.6	10
504	Cytotoxicity of new duplex drugs linking 3â€²â€Câ€ethynylcytidine and 5â€fluorâ€2â€²â€deoxyuridine against human melanoma cells. International Journal of Cancer, 2012, 131, 2165-2174.	2.3	10

#	Article	IF	Citations
505	The role of radiotherapy in the overall treatment of melanoma. Clinics in Dermatology, 2013, 31, 282-289.	0.8	10
506	Effective Combination of Photodynamic Therapy and Imiquimod 5% Cream in the Treatment of Actinic Keratoses: Three Cases. BioMed Research International, 2013, 2013, 1-5.	0.9	10
507	Expanded access programmes: patient interests versus clinical trial integrity. Lancet Oncology, The, 2015, 16, 15-17.	5.1	10
508	Development of a Microsimulation of Melanoma Mortality for Evaluating the Effectiveness of Population-Based Skin Cancer Screening. Medical Decision Making, 2015, 35, 243-254.	1.2	10
509	Decreased Plasma Ascorbate Levels in Stage IV Melanoma Patients. Metabolism and Nutrition in Oncology, 2015, 01, e2-e6.	0.2	10
510	Genomic features of complete responders (CR) versus fast progressors (PD) in patients with BRAFV600-mutated metastatic melanoma treated with cobimetinib + vemurafenib or vemurafenib alone. Annals of Oncology, 2016, 27, vi379.	0.6	10
511	Imaging of gastrointestinal melanoma metastases: Correlation with surgery and histopathology of resected specimen. European Radiology, 2017, 27, 2538-2545.	2.3	10
512	Diagnostic Performance of a Support Vector Machine for Dermatofluoroscopic Melanoma Recognition: The Results of the Retrospective Clinical Study on 214 Pigmented Skin Lesions. Diagnostics, 2019, 9, 103.	1.3	10
513	Position statement on classification of basal cell carcinomas. Part 1: unsupervised clustering of experts as a way to build an operational classification of advanced basal cell carcinoma based on pattern recognition. Journal of the European Academy of Dermatology and Venereology, 2021, 35, 1949-1956.	1.3	10
514	Neural crest cell migration of mouse B16-F1 melanoma cells transplanted into the chick embryo is inhibited by the BMP-antagonist noggin. International Journal of Oncology, 2007, 31, 1367-78.	1.4	10
515	Early disappearance of tumor antigen-reactive T cells from peripheral blood correlates with superior clinical outcomes in melanoma under anti-PD-1 therapy. , 2021, 9, e003439.		10
516	Identification of genes specifically regulated in human melanoma cells. Archives of Dermatological Research, 1995, 287, 421-427.	1.1	9
517	Cutaneous melanoma: baseline and ongoing laboratory evaluation. Dermatologic Therapy, 2005, 18, 413-421.	0.8	9
518	Neural crest cell migration of mouse B16-F1 melanoma cells transplanted into the chick embryo is inhibited by the BMP-antagonist noggin. International Journal of Oncology, 0, , .	1.4	9
519	Protein kinase inhibitors in melanoma. Expert Opinion on Pharmacotherapy, 2013, 14, 2195-2201.	0.9	9
520	Malignes Melanom S3-Leitlinie â€œDiagnostik, Therapie und Nachsorge des Melanomsâ€• JDDG - Journal of the German Society of Dermatology, 2013, 11, 1-126.	0.4	9
521	Study protocol for a prospective, non-controlled, multicentre clinical study to evaluate the diagnostic accuracy of a stepwise two-photon excited melanin fluorescence in pigmented lesions suspicious for melanoma (FLIMMA study). BMJ Open, 2016, 6, e012730.	0.8	9
522	Talimogene laherparepvec (T-VEC) in combination (combo) with ipilimumab (ipi) versus ipi alone for advanced melanoma: 3-year landmark analysis of a randomized, open-label, phase II trial. Annals of Oncology, 2019, 30, v906-v907.	0.6	9

#	Article	IF	Citations
523	Are Pathogenic Germline Variants in Metastatic Melanoma Associated with Resistance to Combined Immunotherapy?. Cancers, 2020, 12, 1101.	1.7	9
524	Circulating Tumor DNA Correlates with Outcome in Metastatic Melanoma Treated by BRAF and MEK Inhibitors â€“ Results of a Prospective Biomarker Study . OncoTargets and Therapy, 2020, Volume 13, 5017-5032.	1.0	9
525	The impact of the COVIDâ€19 pandemic on diagnostic delay of skin cancer: a call to restart screening activities. Journal of the European Academy of Dermatology and Venereology, 2021, 35, e836-e837.	1.3	9
526	Primï¿½re Diagnose, Ausbreitungsdiagnostik und Prognoseschï¿½tzung des malignen Melanoms. Onkologe, 1996, 2, 441-448.	0.7	9
527	Prothymosin alpha augments deficient antitumor activity of monocytes from melanoma patients in vitro. Anticancer Research, 1994, 14, 2405-11.	0.5	9
528	Prognostic impact of the type of anaesthesia used during the excision of primary cutaneous melanoma. Melanoma Research, 2000, 10, 165-169.	0.6	9
529	Inactivation of ribonucleotide reductase in tumour cells and inhibition of tumour cell growth by p-alkoxyphenols. Melanoma Research, 1997, 7, 288-298.	0.6	8
530	Absence of merkel cell polyoma virus in cutaneous melanoma. Experimental Dermatology, 2011, 20, 78-79.	1.4	8
531	Melanoma cells in distinct growth phases retain specific invasive qualities during brain metastasis in vivo. Pigment Cell and Melanoma Research, 2012, 25, 113-114.	1.5	8
532	Combined immunotherapyâ€”a new standard in metastatic melanoma?. Nature Reviews Clinical Oncology, 2015, 12, 439-440.	12.5	8
533	The safety and efficacy of cobimetinib for the treatment of BRAF V600E or V600K melanoma. Expert Review of Anticancer Therapy, 2016, 16, 705-715.	1.1	8
534	Age as key factor for pattern, timing, and extent of distant metastasis in patients with cutaneous melanoma: A study of the German Central Malignant Melanoma Registry. Journal of the American Academy of Dermatology, 2019, 80, 1299-1307.e7.	0.6	8
535	Expression of DNA Methyltransferase 1 Is a Hallmark of Melanoma, Correlating with Proliferation and Response to B-Raf and Mitogen-Activated Protein Kinase Inhibition in Melanocytic Tumors. American Journal of Pathology, 2020, 190, 2155-2164.	1.9	8
536	MelanozytÃre NÃvi und Melanomrisiko: Leitlinien fÃ¼r die Betreuung und Therapie. , 1997, , 215-230.		8
537	Effects of Interferons and Cytokines on Melanoma Cells.. Journal of Investigative Dermatology, 1993, 100, 239S-244S.	0.3	8
538	Absolute and relative differential blood count predicts survival of AJCC stage Iâ€II melanoma patients scheduled for sentinel lymph node biopsy. Australasian Journal of Dermatology, 2020, 61, e310-e318.	0.4	8
539	Survival of SLNB-positive melanoma patients with and without complete lymph node dissection: A multicenter, randomized DECOG trial.. Journal of Clinical Oncology, 2015, 33, LBA9002-LBA9002.	0.8	8
540	Five-year analysis on the long-term effects of dabrafenib plus trametinib (D + T) in patients with BRAF V600â€“mutant unresectable or metastatic melanoma.. Journal of Clinical Oncology, 2019, 37, 9507-9507.	0.8	8

#	Article	IF	Citations
541	A Novel Role for Relaxin-2 in the Pathogenesis of Primary Varicosis. PLoS ONE, 2012, 7, e39021.	1.1	8
542	Diagnostic Accuracy of Electrical Impedance Spectroscopy in Non-melanoma Skin Cancer. Acta Dermato-Venereologica, 2020, 100, adv00328.	0.6	8
543	Cytokines in human melanoma cells: synthesis, autocrine stimulation and regulatory functions--an overview. Melanoma Research, 1993, 3, 425-33.	0.6	8
544	Failure of gadopentetate dimeglumine-enhanced, high-resolution magnetic resonance imaging to differentiate among melanin-containing skin tumors. Academic Radiology, 1996, 3, 186-191.	1.3	7
545	Additional reverse transcription-polymerase chain reaction of peripheral slices is not superior to analysis of the central slice in sentinel lymph nodes from melanoma patients. British Journal of Dermatology, 2004, 150, 477-483.	1.4	7
546	Successful Treatment With Vemurafenib in BRAF V600Kâ€“Positive Cerebral Melanoma Metastasis. JAMA Dermatology, 2013, 149, 642.	2.0	7
547	Nested Melanoma, A Newly Defined Entity. JAMA Dermatology, 2013, 149, 905.	2.0	7
548	Molecular genetic classification of difficult melanocytic tumors. JDDG - Journal of the German Society of Dermatology, 2013, 11, 11-18.	0.4	7
549	How to use neoadjuvant medical treatment to maximize surgery in melanoma. Expert Review of Anticancer Therapy, 2018, 18, 121-130.	1.1	7
550	Patientenakzeptanz und â€vertrauen in die automatisierte, computergestÃ¼tzte Diagnostik des Melanoms mithilfe der Dermatofluoroskopie. JDDG - Journal of the German Society of Dermatology, 2018, 16, 854-860.	0.4	7
551	Meningeal enhancement depicted by magnetic resonance imaging in tumor patients: neoplastic meningitis or therapy-related enhancement?. Neuroradiology, 2019, 61, 775-782.	1.1	7
552	Quality of life in patients with BRAF-mutant melanoma receiving the combination encorafenib plus binimetinib: Results from a multicentre, open-label, randomised, phase III study (COLUMBUS). European Journal of Cancer, 2021, 152, 116-128.	1.3	7
553	Protein Patterns of Benign and Malignant Human Melanocytes Show Consistent Changes in Gene Expression. Recent Results in Cancer Research, 1995, 139, 123-135.	1.8	7
554	Proteogenomics Reveals Perturbed Signaling Networks in Malignant Melanoma Cells Resistant to BRAF Inhibition. Molecular and Cellular Proteomics, 2021, 20, 100163.	2.5	7
555	Development of an Image Analysis-Based Prognosis Score Using Googleâ€™s Teachable Machine in Melanoma. Cancers, 2022, 14, 2243.	1.7	7
556	Identification of genes specifically regulated in melanoma cells. Melanoma Research, 1993, 3, 72.	0.6	6
557	P26b Outcome of sentinel node negative patients with primary cutaneous melanoma-prognostic factors and survival probabilities. Melanoma Research, 2010, 20, e54-e55.	0.6	6
558	Meeting Report from the Third Global Workshop on Melanoma. Pigment Cell and Melanoma Research, 2010, 23, e1-e7.	1.5	6

#	Article	IF	Citations
559	Histopathologische Befundung maligner Melanome in Ãœbereinstimmung mit der AJCC-Klassifikation 2009: LiteraturÃ¼bersicht und Empfehlungen zum praktischen Vorgehen. JDDG - Journal of the German Society of Dermatology, 2011, 9, 690-700.	0.4	6
560	Cutaneous side effects of combined therapy with sorafenib and pegylated interferon alphaâ€2b in metastatic melanoma (phase II DeCOG trial). JDDG - Journal of the German Society of Dermatology, 2013, 11, 846-853.	0.4	6
561	S1â€Leitlinie Dermatofibrosarcoma protuberans (DFSP) â€“ Update 2018. JDDG - Journal of the German Society of Dermatology, 2019, 17, 663-668.	0.4	6
562	Adjuvant immunotherapy with nivolumab (NIVO) alone or in combination with ipilimumab (IPI) versus placebo in stage IV melanoma patients with no evidence of disease (NED): A randomized, double-blind phase II trial (IMMUNED). Annals of Oncology, 2019, 30, v903-v904.	0.6	6
563	Neoadjuvant and adjuvant end-points in health technology assessment in oncology. European Journal of Cancer, 2021, 147, 40-50.	1.3	6
564	Klinik und Histologie des malignen Melanoms. , 1997, , 247-270.		6
565	Dysplastic Nevi-Dysplastic Nevus Syndromes: Clinical Features and Genetic Aspects. Recent Results in Cancer Research, 1993, 128, 101-118.	1.8	6
566	An open-label, single-arm, phase II trial of buparlisib in patients with melanoma brain metastases not eligible for surgery or radiosurgeryâ€"the BUMPER study. Neuro-Oncology Advances, 2020, 2, vdaa140.	0.4	6
567	TMB and BRAF mutation status are independent predictive factors in high-risk melanoma patients with adjuvant anti-PD-1 therapy. Journal of Cancer Research and Clinical Oncology, 2023, 149, 833-840.	1.2	6
568	Efficacy and safety of sequencing with vemurafenib (V) plus cobimetinib (C) followed by atezolizumab (Atezo) in patients (pts) with advanced BRAF^{V600}-positive melanoma: Interim analysis of the ImmunoCobiVem study.. Journal of Clinical Oncology, 2022, 40, 9548-9548.	0.8	6
569	Onkogenetik des Melanoms: Grundlage fÃ¼r molekulare Diagnostik und Therapie. JDDG - Journal of the German Society of Dermatology, 2011, 9, 510-517.	0.4	5
570	Limited efficacy of intratumoral IL-2 applied to large melanoma metastases. Cancer Immunology, Immunotherapy, 2014, 63, 1231-1232.	2.0	5
571	Partial Histological Tumor Regression in Primary Melanoma as Protective Factor for Lymph Node Micrometastasis. JAMA Dermatology, 2015, 151, 1291.	2.0	5
572	The iris signal: blue periphery, tan collaret and freckles pattern â€“ strong indicators for epidermal skin cancer in Southâ€Eastern Europe. Journal of the European Academy of Dermatology and Venereology, 2018, 32, 1662-1667.	1.3	5
573	Embryonic bone morphogenetic protein and nodal induce invasion in melanocytes and melanoma cells. Biology Open, 2018, 7, .	0.6	5
574	Intraprocedural 3D perfusion measurement during chemoembolisation with doxorubicin-eluting beads in liver metastases of malignant melanoma. European Radiology, 2018, 28, 1456-1464.	2.3	5
575	Modifiable Risk-factors for Keratinocyte Cancers in Australia: A Case-control Study. Acta Dermato-Venereologica, 2019, 99, 404-411.	0.6	5
576	Perspectives in melanoma: meeting report from the â€œMelanoma Bridgeâ€•(December 5thâ€“7th, 2019,) Tj ETQq0 0 0 rgBT /Overlock	1.8	5

#	Article	IF	Citations
577	Influence of 18F-FDG PET/CT on clinical management and outcome in patients with advanced melanoma not primarily selected for surgery based on a linked evidence approach. European Journal of Nuclear Medicine and Molecular Imaging, 2020, 47, 2313-2321.	3.3	5
578	Which medical disciplines diagnose and treat melanoma in Europe in 2019? A survey of experts from melanoma centres in 27 European countries. Journal of the European Academy of Dermatology and Venereology, 2021, 35, 1119-1132.	1.3	5
579	PET/CT in malignant melanoma: a twoâ€tiered healthcare system? Updated healthcare situation regarding initial staging of malignant melanoma with PET/CT. JDDG - Journal of the German Society of Dermatology, 2021, 19, 852-862.	0.4	5
580	MelanozytÃre NÃvi und malignes Melanom. , 2003, , 593-649.		5
581	Survival in a phase III, randomized, double-blind study of dacarbazine with or without oblimersen (Bcl-2 antisense) in patients with advanced melanoma and low-normal serum lactate dehydrogenase (LDH; AGENDA).. Journal of Clinical Oncology, 2011, 29, 8531-8531.	0.8	5
582	Variables that influence BRAF mutation probability: A next-generation sequencing, non-interventional investigation of BRAFV600 mutation status in melanoma. PLoS ONE, 2017, 12, e0188602.	1.1	5
583	Disseminated Malignant Melanoma.. International Journal of Dermatology, 1991, 30, 239-242.	0.5	4
584	Management of primary and metastasized melanoma in Germany in the time period 1976â€“2005: an analysis of the Central Malignant Melanoma Registry of the German Dermatological Society. Melanoma Research, 2008, 18, 112-119.	0.6	4
585	No evidence of viral genomes in wholeâ€transcriptome sequencing of three melanoma metastases. Experimental Dermatology, 2011, 20, 766-768.	1.4	4
586	Expression of oxytocin and its receptor in healthy and varicose great saphenous veins. Pathology, 2012, 44, 670-673.	0.3	4
587	The prognostic impact of specific CD4 T-cell responses is critically dependent on the target antigen in melanoma. OncoImmunology, 2015, 4, e955683.	2.1	4
588	Prognostic impact of tumour burden measured by quantitative real-time PCR from sentinel lymph nodes of melanoma patients: data from 10-year follow-up. Journal of Cancer Research and Clinical Oncology, 2017, 143, 703-708.	1.2	4
589	Pembrolizumabâ€induced hepatitis: diagnosis and treatment. JDDG - Journal of the German Society of Dermatology, 2017, 15, 933-935.	0.4	4
590	Effects of Molecular Heterogeneity on Survival of Patients With BRAFV600-Mutated Melanoma Treated With Vemurafenib With or Without Cobimetinib in the coBRIM Study. JCO Precision Oncology, 2018, 2, 1-18.	1.5	4
591	Posterior reversible encephalopathy syndrome in a melanoma patient with dabrafenib and trametinib treatment following immunotherapy. JDDG - Journal of the German Society of Dermatology, 2020, 18, 136-139.	0.4	4
592	Late recurrence of melanoma after 10Âyears â€“ Is the course of the disease different from early recurrences?. Journal of the European Academy of Dermatology and Venereology, 2020, 34, 977-983.	1.3	4
593	Comment on â€˜Diagnosis and treatment of basal cell carcinoma: European consensus-based interdisciplinary guidelinesâ€™. European Journal of Cancer, 2020, 131, 100-103.	1.3	4
594	Psychological Distress of Metastatic Melanoma Patients during Treatment with Immune Checkpoint Inhibitors: Results of a Prospective Study. Cancers, 2021, 13, 2642.	1.7	4

#	Article	IF	Citations
595	Prolonged survival of 2 years or longer for patients with disseminated melanoma. Cancer, 1997, 79, 2345-2353.	2.0	4
596	433â€…Talimogene laherparepvec (T-VEC) in combination with ipilimumab (IPI) versus IPI alone for advanced melanoma: 4-year interim analysis of a randomized, open-label, phase 2 trial. , 2020, 8, A459-A459.		4
597	THE INFLUENCE OF THE THYMIC PREPARATION THYMEX-L ON DEFICIENT ANTITUMOR-ACTIVITY OF MONOCYTES FROM MELANOMA PATIENTS IN-VITRO. Oncology Reports, 1995, 2, 469-72.	1.2	4
598	Malignes Melanom. , 1998, , 799-829.		4
599	Proliferation and morphology of melanoma cells and benign human melanocytes under varying culture conditions. Melanoma Research, 1993, 3, 107-12.	0.6	4
600	Differenzialdiagnose pigmentierter Hautverï¿½nderungen und Melanombehandlung am unteren Genitaltrakt der Frau. Onkologe, 2000, 6, 1083-1090.	0.7	3
601	Epidemiologie, PrÃvention und Nachsorge maligner Melanome. Onkologe, 2001, 7, 18-35.	0.7	3
602	Malignant Melanoma: Classification and Staging of Malignant Melanoma. , 2005, 39, 149-158.		3
603	Oncogenetics of melanoma: basis for molecular diagnostics and therapy. JDDG - Journal of the German Society of Dermatology, 2011, 9, 510-516.	0.4	3
604	Ipilimumab with fotemustine in metastatic melanoma. Lancet Oncology, The, 2012, 13, 851-852.	5.1	3
605	New Diagnostic Method for Lesions With Transepidermal Melanocytic Migration. JAMA Dermatology, 2014, 150, 654.	2.0	3
606	Safety of shortened infusion times for combined ipilimumab and nivolumab. Cancer Immunology, Immunotherapy, 2018, 67, 135-140.	2.0	3
607	Quality assurance in melanoma care: The EU-MELACARE study. European Journal of Surgical Oncology, 2018, 44, 1773-1778.	0.5	3
608	Harmonisation of Outcome Parameters and Evaluation (HOPE) for actinic keratosis: protocol for the development of a core outcome set. Trials, 2019, 20, 589.	0.7	3
609	Dermatofluoroscopy diagnostics in different pigmented skin lesions: Strengths and weaknesses. JDDG - Journal of the German Society of Dermatology, 2020, 18, 682-690.	0.4	3
610	The Great Debate at â€˜Immunotherapy Bridgeâ€™, Naples, December 5, 2019. , 2020, 8, e000921.		3
611	Prognostic role of gamma-glutamyl transferase in metastatic melanoma patients treated with immune checkpoint inhibitors. Cancer Immunology, Immunotherapy, 2021, 70, 1089-1099.	2.0	3
612	Online consensus conferences for the development and update of clinical practice guidelines: A survey among participants of the German S3 guideline on actinic keratosis and cutaneous squamous cell carcinoma. JDDG - Journal of the German Society of Dermatology, 2021, 19, 608-610.	0.4	3

#	Article	IF	Citations
613	1041MO 5-year update on COLUMBUS: A randomized phase III trial of encorafenib (enco) + binimetinib (bini) versus enco or vemurafenib (vem) in patients (pts) with BRAF V600-mutant melanoma. Annals of Oncology, 2021, 32, S872-S873.	0.6	3
614	New Promises in the Adjuvant, and Palliative Treatment of Melanoma. Cancer Treatment and Research, 2007, 135, 277-292.	0.2	3
615	Photodynamic Action of Ultraviolet A: Induction of Cellular Hydroperoxides. Recent Results in Cancer Research, 1995, 139, 43-55.	1.8	3
616	Overall survival in COMBI-d, a randomized, double-blinded, phase III study comparing the combination of dabrafenib and trametinib with dabrafenib and placebo as first-line therapy in patients (pts) with unresectable or metastatic BRAF V600E/Kmutation-positive cutaneous melanoma.. Journal of Clinical Oncology, 2015, 33, 102-102.	0.8	3
617	Quality-of-life (QOL) assessment in patients (pts) with metastatic melanoma receiving vemurafenib (V) and cobimetinib (C).. Journal of Clinical Oncology, 2015, 33, 9021-9021.	0.8	3
618	Adverse events of special interest in the phase 3 COLUMBUS study.. Journal of Clinical Oncology, 2018, 36, 9567-9567.	0.8	3
619	Malignes Melanom. , 1995, , 674-702.		3
620	Real-world Treatment Patterns and Outcomes with Systemic Therapies in Unresectable Locally Advanced and Metastatic Cutaneous Squamous Cell Carcinoma in Germany. Acta Dermato-Venereologica, 2021, 102, adv00637.	0.6	3
621	Acquired Haemophilia Mimicking Dermatitis Artefacta. Acta Dermato-Venereologica, 2008, 89, 194-195.	0.6	3
622	4th ANNUAL MEETING OF THE EUROPEAN SOCIETY FOR PIGMENT CELL RESEARCH Berlin, Germany, September 17â€“19, 1992. Pigment Cell & Melanoma Research, 1992, 5, 168-168.	4.0	2
623	Synergistic interactions between interferon? and carboplatin on SK-MEL 28 human melanoma cell growth inhibition in vitro. Journal of Cancer Research and Clinical Oncology, 1995, 121, 84-88.	1.2	2
624	Fine needle aspiration in the diagnosis of metastatic melanoma. Journal of the American Academy of Dermatology, 2002, 46, 147-148.	0.6	2
625	The PI3K inhibitor LY294002 and the mTOR inhibitor rapamycin sensitize melanoma cells to cisplatin and temozolomide. Melanoma Research, 2006, 16, S94.	0.6	2
626	Dipeptidyl peptidase II is not a marker for progression in melanoma. Journal of Dermatological Science, 2009, 53, 68-71.	1.0	2
627	Meeting report: consensus from the first and second Global Workshops in Melanoma November 19â€“20, 2008. Pigment Cell and Melanoma Research, 2009, 22, 532-543.	1.5	2
628	P35 Status quo of the S3 guideline â€˜Diagnosis, treatment and follow-up of melanomaâ€™ in Germany. Melanoma Research, 2010, 20, e58-e59.	0.6	2
629	In Reply: Sentinel Lymph Node Biopsy in Melanoma. Annals of Surgical Oncology, 2011, 18, 598-599.	0.7	2
630	Patterns of sun protection for young children: do we deliver the right sun-protection messages?. British Journal of Dermatology, 2012, 166, 710-710.	1.4	2

#	Article	IF	Citations
631	Follow-up in patients with low-risk cutaneous melanoma: is it worth it?. Melanoma Management, 2014, 1, 115-125.	0.1	2
632	Quality-of-life (QoL) in COLUMBUS part 1: A phase 3 trial of encorafenib (ENCO) plus binimetinib (BINI) versus vemurafenib (VEM) or ENCO in braf-mutant melanoma. Annals of Oncology, 2017, 28, v442.	0.6	2
633	Immunotherapy Bridge 2017 and Melanoma Bridge 2017: meeting abstracts. Journal of Translational Medicine, 2018, 16, .	1.8	2
634	Leitlinien und QualitÃtssicherung fÃ¼r Diagnose und Therapie des malignen Melanoms. , 1998, , 254-261.		2
635	Open-label, multicenter, single-arm phase II study (DeCOG-Trial) to further evaluate the efficacy and safety of ipilimumab in patients with cutaneous melanoma and rare subgroups.. Journal of Clinical Oncology, 2014, 32, 9031-9031.	0.8	2
636	Intralesional treatment of stage III metastatic melanoma patients with L19-IL2: Clinical and systemic immunological responses.. Journal of Clinical Oncology, 2014, 32, 9041-9041.	0.8	2
637	A phase II, single-armed, multicenter trial of neoadjuvant vismodegib in patients with large and/or recurrent basal cell carcinoma: NICCI.. Journal of Clinical Oncology, 2014, 32, TPS9116-TPS9116.	0.8	2
638	Nivolumab (NIVO) safety in patients with advanced melanoma (MEL) who have progressed on or after ipilimumab (IPI): A single-arm, open-label, multicenter, phase II study (CheckMate 172).. Journal of Clinical Oncology, 2016, 34, 9526-9526.	0.8	2
639	Clinical validation of a prognostic 11-gene assay in prospectively collected FFPE tissue of patients with AJCC v8 stage II cutaneous melanoma (CM).. Journal of Clinical Oncology, 2019, 37, 9518-9518.	0.8	2
640	Acquired resistance mechanisms to immunotherapy. Annals of Translational Medicine, 2016, 4, 547-547.	0.7	2
641	Phase I/II study of the tumor-targeting human L19-IL2 monoclonal antibody-cytokine fusion protein in combination with DTIC in metastatic melanoma patients. Journal of Clinical Oncology, 2009, 27, 9064-9064.	0.8	2
642	Prognoseverbesserung durch KontinuitÃtsdissektion nach Lymphabstromszintigraphie bei Rumpfmelanomen. Fortschritte Der Operativen Dermatologie, 1995, , 251-258.	0.1	2
643	Nachsorge bei Melanompatienten. , 1997, , 407-413.		2
644	Combined treatment of metastatic melanoma with interferons and cytotoxic drugs. Seminars in Oncology, 1992, 19, 63-9.	0.8	2
645	Change of epidemiological characteristics of malignant melanoma during the years 1962-1972 and 1983-1986 in the Federal Republic of Germany. Dermatologica, 1989, 178, 131-5.	0.1	2
646	Persistent scleredema of Buschke in a diabetic: improvement with high-dose penicillin. British Journal of Dermatology, 1996, 134, 597-8.	1.4	2
647	Dynamics of Melanoma-Associated Epitope-Specific CD8+ T Cells in the Blood Correlate With Clinical Outcome Under PD-1 Blockade. Frontiers in Immunology, 0, 13, .	2.2	2
648	Adjuvante Interferon Î±â^' Therapie beim Melanom. Onkologe, 1998, 4, 256-259.	0.7	1

#	Article	IF	Citations
649	11 The adjuvant study programme of the dermatologic co-operative oncology group (DeCOG). Melanoma Research, 1999, 9, 312.	0.6	1
650	Differential diagnosis of pigmented skin changes and the treatment of melanoma of the lower genital tract in women. Der Gynakologe, 2001, 34, 634-640.	1.0	1
651	Frï¿½herkennung verbessern!. Onkologe, 2004, 10, 683.	0.7	1
652	Upregulated expression of the Y-box binding protein 1 (YB-1) in melanoma cells enforces melanoma cell proliferation, survival and invasion and increases chemoresistance. Melanoma Research, 2006, 16, S104.	0.6	1
653	FC10 Sorafenib and pegylated interferon alpha 2b in advanced metastatic melanoma: a multicenter phase II DeCOG trial. Melanoma Research, 2010, 20, e33.	0.6	1
654	FC22 3.0% diclofenac in 2.5% hyaluronic acid inverts the process of cancerous transformation in actinic keratoses and maintains therapeutic response by prolongation of treatment. Melanoma Research, 2010, 20, e39.	0.6	1
655	Statement on the Letters to the Editors by Starz and Bahmer. JDDG - Journal of the German Society of Dermatology, 2012, 10, 205-205.	0.4	1
656	Molekulargenetische Klassifikation schwieriger melanozytÃrer Tumoren. JDDG - Journal of the German Society of Dermatology, 2013, 11, 12-19.	0.4	1
657	A Phase 1B/2, Multicenter, Open Label Trial to Evaluate the Safety and Efficacy of Talimogene Laherparepvec (T-Vec) and Ipilimumab (Ipi) Versus Ipi Alone in Previously Untreated, Unresected, Stage Iiib, Iiic, and Iv Melanoma. Annals of Oncology, 2014, 25, iv391.	0.6	1
658	Combi-D: Quality of Life (Qol) Impact of the Combination of Dabrafenib and Trametinib (D + T) Versus Dabrafenib Monotherapy (D) in Patients with Braf V600E/K Unresectable or Metastatic Melanoma in a Phase III Trial. Annals of Oncology, 2014, 25, iv377.	0.6	1
659	Interessante Frage: Welche anderen Tumoren werden in der Melanomâ€Nachsorge mittels PETâ€CT entdeckt?. JDDG - Journal of the German Society of Dermatology, 2016, 14, 761-762.	0.4	1
660	Hospitalization Rates in COLUMBUS Part 1: A Phase 3 Trial of Encorafenib (ENCO) Plus Binimetinib (BINI) Versus Vemurafenib (VEM) or ENCO in BRAF-Mutant Melanoma. Annals of Oncology, 2017, 28, v441.	0.6	1
661	Acral Lentiginous Melanoma. , 2019, , 1-28.		1
662	BRAF mutation testing in melanoma: results from a German observational multicenter study. Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin, 2019, 474, 71-78.	1.4	1
663	Response to: Comment on â€˜Diagnosis and treatment of basal cell carcinoma: European consensus-based interdisciplinary guidelinesâ€™. European Journal of Cancer, 2020, 140, 154-157.	1.3	1
664	Mucosal Melanoma. , 2019, , 1-17.		1
665	MelanozytÃre NÃvi und MelanomvorlÃufer. , 2002, , 895-929.		1
666	Abstract 5506: Trabedersen (AP 12009) for the treatment of patients with advanced tumors: A phase I/II study. , 2011, , .		1

#	Article	IF	Citations
667	Results of pooled analyses from two phase III trials of 1,085 patients (pts) with advanced melanoma: Oblimersen (OBL) plus dacarbazine (DTIC) versus DTIC alone.. Journal of Clinical Oncology, 2010, 28, 8573-8573.	0.8	1
668	Evaluation of photosensitivity in dabrafenib treated metastatic melanoma patients: Results from a phase IIa study.. Journal of Clinical Oncology, 2016, 34, e21077-e21077.	0.8	1
669	The demand for psycho-oncological support in 820 melanoma patients: What are the determinants for the development of distress?. Journal of Clinical Oncology, 2017, 35, 9514-9514.	0.8	1
670	HIV-Infektion und Kaposi-Sarkom. , 2002, , 1015-1074.		1
671	Sonnenschutz: Was ist zuviel, was ist zuwenig?. Fortschritte Der Praktischen Dermatologie Und Venerologie, 2005, , 504-511.	0.0	1
672	Epidemiologie des malignen Melanoms. , 1991, , 1-14.		1
673	Malignes Melanom. , 1993, , 229-250.		1
674	Pseudolymphome, PrÃlymphome und Lymphome der Haut. , 1995, , 987-1020.		1
675	Adjuvant therapy with pegylated interferon alfa-2a (PEG-IFN) versus low-dose interferon alfa-2a (IFN) in patients with malignant melanoma in stages IIa(T3a): IIIb (AJCC 2002)â€"Decog-trial.. Journal of Clinical Oncology, 2014, 32, 9071-9071.	0.8	1
676	An open-label, uncontrolled, single arm phase II trial of the PI3K inhibitor buparlisib in patients with melanoma brain metastases.. Journal of Clinical Oncology, 2017, 35, TPS9595-TPS9595.	0.8	1
677	Next-generation-sequencing of advanced melanoma: Which genetic alterations have an impact on systemic therapy response?. Journal of Clinical Oncology, 2018, 36, e21557-e21557.	0.8	1
678	Individualized Proteogenomics Reveals the Mutational Landscape of Melanoma Patients in Response to Immunotherapy. Cancers, 2021, 13, 5411.	1.7	1
679	Diagnostic and prognostic classification of atypical spitzoid tumours based on histology and genomic aberrations: A prospective cohort study with long-term follow-up. European Journal of Cancer, 2022, 163, 200-210.	1.3	1
680	Is isolated limb perfusion of metastatic malignant melanoma of the extremity worthwhile?. European Journal of Cancer, 1996, 32, 1635-1638.	1.3	0
681	Development of Melanocytic Nevi in Children-Reply. Archives of Dermatology, 1997, 133, 1049.	1.7	0
682	FrÃ¼herkennung von Hautkrebs. Onkologe, 2002, 8, 1064-1071.	0.7	0
683	Malignant blue naevus of the scalp. Lancet Oncology, The, 2004, 5, 429.	5.1	0
684	A first-line, phase II study with dacarbazine (DTIC) plus thymosin alpha 1 (Ta1) with or without interferon alpha (IFNa) vs. DTIC plus IFNa in stage IV melanoma. Melanoma Research, 2006, 16, S39.	0.6	0

#	Article	IF	Citations
685	Hepatic hemangioma and hemochromatosis misdiagnosed by MRI as metastatic melanoma. JDDG - Journal of the German Society of Dermatology, 2011, 9, 842-843.	0.4	0
686	Fehldiagnose von Lebermetastasen eines Melanoms durch MRT bei LeberhÃmagiomen und HÃmochromatose. JDDG - Journal of the German Society of Dermatology, 2011, 9, 842-843.	0.4	0
687	MelanozytÃre NÃvi und Melanom. , 2015, , 1-87.		0
688	Targeted Therapies for Melanoma. , 2015, , 1529-1541.		0
689	Screening for skin cancer in bank and insurance employees: risk profile and correlation of self and physician's assessment. International Journal of Dermatology, 2015, 54, 419-423.	0.5	0
690	More than 5000 patients with metastatic melanoma in Europe per year do not have access to new life-saving drugs. Annals of Oncology, 2016, 27, vi586.	0.6	0
691	Reply to â€˜Recent advances in systemic targeted therapy for cutaneous T-cell lymphomaâ€™. Expert Opinion on Pharmacotherapy, 2017, 18, 1537-1537.	0.9	0
692	Kein Ãœberlebensvorteil beim Sentinelâ€Lymphknotenâ€positiven Melanom mit sofortiger kompletter Lymphadenektomie â€“ eine Ãœbersicht. JDDG - Journal of the German Society of Dermatology, 2019, 17, 7-14.	0.4	0
693	Toxic epidermal necrolysis in a melanoma patient under targeted therapy with encorafenib and binimetinib. JDDG - Journal of the German Society of Dermatology, 2020, 18, 1159-1161.	0.4	0
694	TMB and BRAF mutation status are independent predictive factors in stage IIIC/D/IV melanoma patients receiving adjuvant PD-1 antibodies.. Journal of Clinical Oncology, 2021, 39, 9524-9524.	0.8	0
695	30Âyears German Dermatologic Cooperative Oncology GroupÂ(DeCOG). JDDG - Journal of the German Society of Dermatology, 2021, 19, 1682-1697.	0.4	0
696	30 Jahre Arbeitsgemeinschaft Dermatologische Onkologie (ADO). JDDG - Journal of the German Society of Dermatology, 2021, 19, 1682-1697.	0.4	0
697	Molekulare Diagnose des malignen Melanoms. , 2000, , 482-485.		0
698	FamiliÃres Melanom. , 2001, , 43-55.		0
699	Melanomnachsorge: Welche Untersuchungen sind sinnvoll?. Fortschritte Der Praktischen Dermatologie Und Venerologie, 2001, , 307-313.	0.0	0
700	Malignes Melanom des Viszerum (PrimÃrtumor und Metastasen). , 2001, , 755-771.		0
701	Pseudolymphome, PrÃlymphome und Lymphome der Haut. , 2002, , 1075-1112.		0
702	Lichtdermatosen und Lichtschutz. , 2002, , 793-813.		0

#	Article	IF	Citations
703	Epitheliale PrÃkanzerosen und Karzinome der Haut. , 2002, , 861-893.		0
704	Sklerodermie und sklerodermiforme Dermatosen. , 2002, , 549-575.		0
705	Kutane Borreliosen. , 2002, , 103-115.		0
706	Sonstige Hauttumoren. , 2002, , 969-983.		0
707	Lupus erythematodes und verwandte Immunopathien einschlieÃŸlich Ãœberlappungssyndromen. , 2002, , 513-535.		0
708	Malignes Melanom. , 2002, , 931-967.		0
709	Dermatoskopie. Fortschritte Der Praktischen Dermatologie Und Venerologie, 2005, , 611-623.	0.0	0
710	Merkel-Zell-Tumor. , 2006, , 5148-5156.		0
711	Cutaneous Metastases of Melanoma: New Treatment Options. , 2009, , 591-598.		0
712	Abstract PR-1: AGENDA: Results of a randomized, doubleâ€blind phase III trial of dacarbazine with or without Bclâ€2 targeted therapy (oblimersen) in a biomarkerâ€defined patient population with advanced melanoma. , 2009, , .		0
713	Malignes Melanom des Viszerum (PrimÃrtumor und Metastasen). , 2010, , 753-772.		0
714	Abstract 5582: NY-ESO-1-specific T-cells in melanoma patients with good clinical outcome after vaccination using mRNA as the immunogen. , 2010, , .		0
715	Rare Tumors of the Skin and Subcutaneous Tissues. Pediatric Oncology, 2012, , 455-482.	0.5	0
716	Epidemiologie des malignen Melanoms: Aktueller Stand in der Bundesrepublik Deutschland. Verhandlungen Der Deutschen Dermatologischen Gesellschaft, 1991, , 71-79.	0.0	0
717	Malignes Melanom: Epidemiologie und Risikofaktoren. Fortschritte Der Praktischen Dermatologie Und Venerologie, 1993, , 149-154.	0.0	0
718	HIV-Infektion und Kaposi-Sarkom. , 1995, , 937-986.		0
719	Zytokintherapien bei malignen Hauttumoren. , 1995, , 1021-1041.		0
720	Alterung und Altershaut. , 1995, , 1281-1303.		0

#	Article	IF	Citations
721	PigmentzellnÃvi und MelanomvorlÃufer. , 1995, , 835-853.		0
722	Lichtdermatosen und Lichtschutz. , 1995, , 729-749.		0
723	Stellenwert der Zytokintherapie in der Dermatoonkologie. Fortschritte Der Operativen Dermatologie, 1995, , 251-257.	0.1	0
724	Kutane Borreliosen. , 1995, , 99-109.		0
725	Malignes Melanom. , 1995, , 855-889.		0
726	Seasonal Patterns in the Diagnosis of Cutaneous Malignant Melanoma due to Differential Detection Rather than Biological Causes. An Analysis of the Data of the German Central Malignant Melanoma Registry. , 1997, , 519-526.		0
727	PrÃvention des malignen Melanoms â€" Strategien, Ergebnisse und Perspektiven in verschiedenen LÃndern. , 1997, , 414-424.		0
728	Recent Epidemiological Trends of Cutaneous Melanoma in Germany, Austria and Switzerland. Results of the Central Malignant Melanoma Registry. , 1997, , 507-518.		0
729	Lymphknotensonographie fÃ¼hrt zur Erstentdeckung von regionÃren Metastasen bei einem Drittel der Patienten mit Melanom. , 1998, , 262-264.		0
730	Die Entwicklung der Ultraschalldiagnostik in der Dermatologie. , 1999, , 1-7.		0
731	Die PrÃvention des Malignen Melanoms: Beispiele aus Australien und Deutschland. Fortschritte Der Operativen Dermatologie, 1999, , 25-34.	0.1	0
732	Quantitative assessment of melanoma spread in sentinel and non-sentinel lymph nodes and survival.. Journal of Clinical Oncology, 2014, 32, 9082-9082.	0.8	0
733	Vemurafenib treatment in patients with BRAF-mutated melanoma failing MEK inhibition with trametinib.. Journal of Clinical Oncology, 2014, 32, 9061-9061.	0.8	0
734	NY-ESO-1 specific CD4⁺ T_{helper}1 cells for immunotherapy of cancer.. Journal of Clinical Oncology, 2014, 32, 3071-3071.	0.8	0
735	Effect of the BRAF inhibitor LGX818 on endoplasmic reticulum stress and sensitivity of NRAS-mutant melanoma cells to the MEK inhibitor binimetinib.. Journal of Clinical Oncology, 2014, 32, 9062-9062.	0.8	0
736	RAGE ligand S100A8/A9 as a novel prognostic biomarker for high-risk melanoma patients.. Journal of Clinical Oncology, 2014, 32, 9070-9070.	0.8	0
737	Senescence induction in human melanoma by the combined action of type II interferon and tumor necrosis factor.. Journal of Clinical Oncology, 2014, 32, e22213-e22213.	0.8	0
738	The GERMELATOX DeCOG-trial: German melanoma patients and their attitude toward toxicity during adjuvant interferon treatment.. Journal of Clinical Oncology, 2014, 32, TPS9113-TPS9113.	0.8	0

#	Article	IF	Citations
739	Abstract 2547: Peripheral immune signatures and survival in stage IV melanoma. , 2014, , .		0
740	Kutane Nebenwirkungen neuer Krebsmedikamente. , 2016, , 305-312.		0
741	MelanozytÃre NÃvi und Melanom. , 2016, , 609-668.		0
742	Interdisciplinary management of central nervous system metastasis and neoplastic meningitis: recent developments and future perspectives. Journal of Cancer Metastasis and Treatment, 2016, 2, 163.	0.5	0
743	Outcome on 560 metastatic melanoma (MM) patients treated with pembrolizumab during the German Expanded Access Program (EAP).. Journal of Clinical Oncology, 2016, 34, 9558-9558.	0.8	0
744	Factors influencing BRAFV600 mutation testing quality in melanoma: Results from a large, non-interventional, multicenter study in Germany.. Journal of Clinical Oncology, 2016, 34, e23142-e23142.	0.8	0
745	Interleukin-2 as anticancer immunotherapy in the age of checkpoint inhibition. Translational Cancer Research, 2016, 5, S313-S314.	0.4	0
746	Fear of progression in patients with low-risk malignant melanoma.. Journal of Clinical Oncology, 2017, 35, e21615-e21615.	0.8	0
747	Abstract 3034:18F-FDG-positron emission tomography (PET)/CT enables the identification of checkpoint inhibitor immunotherapy (CIT) responders by determination of CIT-induced metabolic changes in secondary lymphatic organs. , 2018, , .		0
748	Melanoma in Children and Teenagers. , 2019, , 1-14.		0
749	Mucosal Melanoma. , 2020, , 953-968.		0
750	Acral Lentiginous Melanoma. , 2020, , 897-924.		0
751	Indirect Comparison of Combined BRAF and MEK Inhibition in Melanoma Patients with Elevated Baseline Lactate Dehydrogenase. Acta Dermato-Venereologica, 2020, 100, adv00174.	0.6	0
752	Melanoma in Children and Teenagers. , 2020, , 969-982.		0
753	Malignes Melanom. , 0, , 898-917.		0
754	Kutane Plattenepithelkarzinome: Maligne Tumoren mit hoher Mutationslast. , 0, , .		0
755	Incidence and mortality of malignant melanoma in Berlin (West) from 1980 to 1986. Acta Dermato-Venereologica, 1991, 71, 506-11.	0.6	0